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Introduction 
 
I. Background 
 
Granulocyte colony-stimulating factor (G-CSF) is in broad clinical use. As a major 
hematopoietic growth factor, G-CSF activates a receptor of the hematopoietic 
receptor superfamily, the G-CSF receptor (G-CSFR). Although the biological and 
clinical effects of G-CSF are relatively well studied, little is known about the G-CSF 
receptor expression in nonhematopoietic tissues. However, such knowledge is 
essential to determine which cells may respond to the administration of G-CSF.  
 
G-CSFR on Neutrophils 
G-CSF is the principal growth factor regulating the maturation, proliferation and 
differentiation of the precursor cells of neutrophilic granulocytes all of which express 
G-SCFR. In addition, some hematopoietic stem and progenitor cells express G-CSFR 
in a stage-specific manner (McKinstry et al., 1997).  
G-CSF is routinely used for stem cell mobilization (Thomas et al., 2002). Since G-
CSF administration reduces the duration of neutropenia, enhance hematopoietic 
reconstitution and increase the progenitor cell yields, it has been used to treat 
idiopathic and iatrogenic neutropenia, as well as postoperative and post-traumatic 
patients at risk of sepsis, even in immunosuppression related neutropenia in organ 
graft recipients (Schmaldienst et al., 2000; Turgeon et al., 2000). 
 
G-CSFR on Monocytes and Lymphocytes 
G-CSF effects as a growth factor in hematopoiesis exceed by far the role of a 
neutrophil recruitment signal, since it also induces the proliferation and mobilization of 
other cells of leukocyte lineage. G-CSF treatment leads to the rapid increase of bone 
marrow cellularity and is also involved in the release of cells from BM into the 
circulation. Furthermore, monocytes and macrophages were also identified to express
G-CSFR (Boneberg et al., 2000), mediating a suppressing effect on inflammatory 
responses by G-CSF. G-CSF attenuates inflammatory responses directly by reducing
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proinflammatory cytokine formation (interleukin-6 (IL-6), tumor necrosis factor-alpha 
(TNF-α), IL-12 and IL-1β) in activated monocytes and macrophages (Attalah et al., 
2002). G-CSF also has an indirect modulatory effect by increasing the number of 
peripheral lymphocytes, and attenuating the release of interferon-gamma (IFN- γ). 
These effects suggest a shift towards the Th2-type response of the specific immune 
system favoring humoral defense (Boneberg, 2000) and stimulation of host immunity. 
G-CSF treatment has shown encouraging results in a broad variety of animal infection 
models in terms of improved survival, reduced bacterial load, enhanced neutrophil 
action and immigration into infected sites (reviewed by Hareng, 2002). In human 
infections, treatment with G-CSF was associated with a reduced risk for postoperative 
infections, accelerated eradication of pathogens from the infected site and reduced 
infection related mortality (Lyman, 2002).   
 
G-CSFR on Endothelial Cells 
In addition to hematopoietic cells, G-CSFR has been detected on vascular endothelial 
cells, suggesting a role in endothelial cell growth and migration. Bussolino reported that 
G-CSF could induce endothelial cells to express G-CSFR and induce proliferation and 
migration leading to angiogenesis in vitro and in vivo (Bussolino et al., 1991). Dogs 
treated with G-CSF have increased endothelialization of synthetic vascular grafts. This 
was attributed to increased number of circulating bone marrow progenitor cells (Shi et 
al., 2002). Moreover, Kocher demonstrated that G-CSF mobilized bone marrow from 
adult humans contains endothelial precursors with phenotypic and functional 
characteristics of embryonic hemangioblast. Thus, it can be used to directly induce 
blood vessel formation in the infarct-bed and proliferation of preexisting vessels after 
experimental myocardial infarction (Kocher et al., 2001). Likewise, Norol reported in 
nonhuman primates submitted to coronary artery ligation, that mobilization of stem cells 
by G-CSF could promote angiogenesis in the infarcted myocardium, without detectable 
myocardial repair (Norol et al., 2003). A less favorable property of G-CSF is its 
potential to promote tumor growth, at least in part, by stimulating angiogenesis in which 
bone marrow-derived endothelial progenitor cells play a role (Natori et al., 2002).                             
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Taken together, various actions of G-CSF are triggered by binding to its receptor, 
thereby activating intracellular signaling cascades. However, the broad clinical use of 
G-CSF stands in strong contrast to the relatively poor understanding of the pattern of 
its receptor expression. Moreover, evaluation of G-CSFR expression may be of 
importance for understanding the reported effect on liver regeneration. This project is 
dedicated to determine the patterns of G-CSFR expression in parenchymal organs of 
rats under different experimental conditions.  
 
II. Aim 
 
As a step toward better understanding the effects of G-CSF, especially the effect on 
liver, the study was designed to investigate the expression of the receptor for G-CSF 
on the mRNA and protein level in rats. The experimental aims were summarized as 
follows: 
− To develop a probe for the detection of G-CSFR transcription 
− To determine the anatomic location of G-CSFR in nonhematopoietic tissues of 
adult rats and thereby elucidate which cells, especially in the liver, express the 
G-CSFR, and therefore may respond to the administration of G-CSF.  
− To study the regulation of G-CSFR expression under different experimental 
conditions 
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Materials and Methods 
 
Investigating the expression and regulation of the expression of G-CSFR requires a 
multistep approach. Reagents have to be generated that allow the demonstration of 
G-CSFR mRNA and protein expression. The cellular distribution of this receptor must 
be pinpointed and kinetic changes of the receptor expression must be demonstrated. 
 
Strategy 
I. Develop a probe for G-CSFR 
1. Design primers for G-CSFR;  
2. DNA and RNA extraction; 
3. Amplify G-CSFR from DNA by polymerase cycle reactions (PCR) and from 
RNA by Reverse transcription polymerase cycle reactions (RT-PCR); 
4. Sequence; 
i.  Sequence PCR products directly   
ii. Clone PCR products   
iii. Sequence insert of plasmid 
5. Design, synthesize and label a single stranded probe. 
      i.  Design probe 
       ii. Generate probe by asymmetric PCR 
                 iii. Label aminoallyl-dUTP incorporated probe 
II. Investigate the G-CSFR mRNA distribution in normal rats. 
1. Isolate RNA and amplify G-CSFR by RT-PCR;  
       i.  Isolate total RNA   
       ii. Perform RT-PCR 
2. Detect the G-CSFR mRNA expression by Northern blot analysis;  
3. Detect the anatomic localization of G-CSFR mRNA by Fluorescence in situ 
hybridization (FISH);  
4. Determine the anatomic localization of G-CSFR protein by immunohisto-
chemistry (IHC). 
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III. Observe the G-CSFR expression in nonhematopoietic organs of G-CSF treated 
and/or 90% hepatectomized (PH) rats  
1. Examine the histological changes after G-CSF treatment and/or 90%PH; 
2. Determine the protein expression of G-CSFR by IHC after G-CSF treatment 
and/or 90% PH. 
Materials 
Reagents and equipments for this project were listed in table 1and 2.  
 
Methods 
I. Probe development for G-CSFR.  
I.1 Primer design for rat G-CSFR  
I.2 DNA and RNA extraction 
I.3 Amplification of G-CSFR from genomic DNA by PCR and from and   
     RNA by RT-PCR 
I.4 Sequencing 
I.5 Designing, synthesizing and labeling single stranded probe 
 
I.1 Primer design for rat G-CSFR 
In order to detect G-CSFR expression, a specific probe is required to screen the 
mRNA distribution. Since there is no commercially probe available and the full-length 
sequence is unavailable in the Genbank database, a specific probe had to be 
designed.  The known sequences of the human and mouse G-CSFR genes were taken
fom the Genbank database (http://www.ncbi.nlm.nih.gov/). Alignment was done  
using the NBRF program ALIGN. Conserved regions were pinpointed and primers
were designed according to the guidelines for primer design (table 3). The Tm
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of pairs of primers was estimated using the Primer Express software (PE Applied 

Biosystems) (list of primers see table 4). 
All primers were generated by MWG Biotech (Ebersberg, Germany).   
I.2 DNA and RNA extraction  
I.2.1 Animals and Samples 
Inbred male Lewis rats (Charels River Wiga GmbH, Germany) were used in the 
experiment. Animals were employed when they reached a body weight of 250~350g. 
They were housed under standard animal care conditions and were fed with standard 
rat chow before and after the operation. Animal housing and procedures were carried 
out according to the German Animal Welfare Legislation.  
After sacrifice, samples of heart, lung, spleen, kidney, liver, small bowel, pancreas 
and BM were snap frozen and stored in liquid nitrogen. Additional tissue samples 
were fixed in 10% buffered formalin. Embedding in paraffin was done using a Tissue 
Processor TPC15 (Medite Inc. Germany). Paraffin blocks were stored at room 
temperature for routine histologic processing and immunohistochemical staining. 
 
I.2.2 DNA and RNA purification 
Genomic DNA was extracted from normal rat liver tissue, obtained during liver 
resection. DNA was extracted by tissue homogenization, proteinase K digestion, 
phenol extraction and ethanol precipitation (for protocol see table 5). RNA was 
extracted from liver of normal rat using a QIAGEN RNeasy RNA purification kit (table 
6) 
Purified products were separated electrophoretically on 2% agarose gels and stained 
with ethidium bromide. The results were documented by photographs under UV-light 
(table 7). 
I.3 Amplification of G-CSFR from DNA by PCR and from RNA by RT-PCR 
Genomic DNA and RNA were used to generate PCR fragments of the G-CSFR gene 
and its transcript. Comparing them revealed the intron and exon structure of the gene. 
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 I.3.1 Touch-down PCR  
Touch-down PCR was performed to facilitate the amplification of the specific G-CSFR 
gene sequence according to the following protocol (table 8).  Since Touch-down PCR 
uses a cycling program with varying annealing temperatures, it enhances the 
specificity of the initial primer-template duplex formation and hence the specificity of 
the final PCR product. Hotstar Taq DNA Polymerase was used in the PCR reaction. It 
was activated by a 10-15 minute incubation at 95ºC which can minimize nonspecific 
amplification products, primer-dimers and background. 
Amplified bands were electrophoresed on 2% agarose gels (table 7). 
 
I.3.2 RT-PCR  
Two step RT-PCR was conducted on total RNA. (table 9) M-MuLV reverse 
transcriptase (MBI, Fermentas, Germany) was used to reverse transcribe the RNA to 
cDNA, followed by Hotstar PCR. 
 
I.3.3 Purification of PCR products 
PCR products were purified using the QIAquick PCR purification kit (table 10). In this 
process additional primers, nucleotides, polymerases, and salts after DNA synthesis 
were removed.  
I.4 Sequencing 
I.4.1 Direct sequencing of PCR products 
Direct sequencing of PCR products was achieved by cycle sequencing. Sequencing 
was performed using an ABI PRISM 310 sequencing Analyzer system (table 11). 
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I.4.2 Cloning 
Double-stranded G-CSFR DNA was cloned into the plasmid pCR4-TOPO. This 
plasmid was transformed into Escherichia coli strain DH5α (table 12). The colonies 
were selected and analyzed by PCR and restriction analysis with EcoR I.  
Plasmids were purified according to the protocols of the QIAGEN plasmid purification 
kit. The procedure included alkaline lysis of the bacteria, followed by binding of the 
plasmid DNA to an Anion-Exchange Resin under appropriate low-salt and pH 
conditions. Plasmid DNA was eluted in a high-salt buffer and then concentrated and 
desalted by isopropanol precipitation (table 13). 
 
I.4.3 Sequencing of plasmid DNA 
Plasmid DNA was sequenced using an ABI PRISM BigDye terminator cycle 
sequencing kit employing M13 primers (forward: 5’-GTA AAA CGA CGG CCA G-3’; 
reverse: 5’-CAG GAA ACA GCT ATG AC-3’) in an ABI PRISM 377 automated 
sequencing system. Analysis of the results were performed with the ABI PRISM GS 
STR POP4, GeneScan Analysis Software. Alignment scores were generated using 
the NBRF program ALIGN using the MD data matrix with a bias of +6 and a gap 
penalty of 6. Sequencing results were confirmed by analyzing samples of five 
independent rats. 
I.5 Probe generation and labeling 
I.5.1 Probe design 
The design of the probe was performed using a set of guidelines  
Probe design and optimization criteria: 
-    Probe length of 200~300bp 
-    specificity of the selected  sequence documented by using the BLAST  
- Considering genomic information to pick an intron spacing region 
- Normalizing GC content / Tm across the whole probe to ensure identical 
hybridization conditions for all parts of the probes 
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- Avoiding secondary structures, such as hairpins and palindromes, for 
minimal self-hybridization 
 
Asymmetric PCR was employed to generate a single-stranded DNA (ssDNA) probe. 
Two different methods were compared to obtain labeled probes.  
I.5.2 Asymmetric PCR 
Plasmid DNA was used as a template. Asymmetric PCR was performed using the 
forward primer at 0.5µM,and the reverse primer at 0.005 µM.  
 
I.5.2.1 Incorporation of fluorescin-12-dUTP 
dTTP was partially replaced by Fluorescin-12-dUTP at a ratio of 3:1 in the PCR 
reaction mix (table 15). The PCR products were purified using the QIAquick PCR 
purification kit (table 10). 
 
I.5.2.2 Incorporation of aminoallyl-dUTP 
dTTP was partially replaced by aminoallyl-dUTP at ratio of 1:2 in the PCR reaction 
mix (table 15). The PCR products were purified before the labeling reaction using the 
QIAquick PCR purification kit (table 10). 
 
I.5.3 Aminoallyl-UTP labeling procedure  
Activated 5/6 Carboxyfluorescein (emp Biotech, Germany) and Cy3 monofunctional 
dye (Amersham Parmacia Biotech, UK) were used in the labeling reaction of  the 
aminoallyl-dUTP containing amplicon (table 13). Excess dye was removed by gel 
filtration through G50 columns before hybridization (table 14).  
Unlabeled nucleotides, Fluorescin-12-dUTP and aminoallyl-dUTP dilution (diluted to 
1/10, 1/102, 1/103, 1/104 and 1/105, irrespectively) were used to compare the 
efficiency of the PCR reaction. One tenth of the amplicons were electrophoresed on 
2% agarose gels (figure 1A). 
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II. Investigation of G-CSFR distribution in normal rats 
II.1 Isolation of total RNA and amplification of G-CSFR by RT-PCR 
II.2 Detection of G-CSFR mRNA expression by Northern blot analysis 
II.3 Detection of the anatomic localization of G-CSFR mRNA by FISH  
II.4 Detection of the anatomic localization of G-CSFR protein by IHC  
 
G-CSFR mRNA expression in normal rats was tested by RT-PCR and Northern 
blotting. The anatomic localization of G-CSFR was demonstrated on the RNA level by 
in situ hybridization using the FISH technique and on the protein level by IHC. 
II.1 Isolation of total RNA and amplification of G-CSFR by RT-PCR 
II.1.1 RNA Isolation  
Total RNA was extracted from 9 organs (liver, heart, lung, kidney, intestine, pancreas, 
lymph node, spleen and bone marrow) of six normal rats employing the QIAGEN 
RNeasy RNA purification kit (table 6). RNA samples were quantified using a 
spectrophotometer (table 7). 
 
II.1.2 RT- PCR 
Reverse transcription was performed using M-MuLV Reverse Transcriptase (table 9). 
The primers used to amplify the DNA fragment encoding part of extracellular region of 
receptor were the same as those used to generate the probe. The expected size of 
the amplicon was 280bp. Verification of equal template concentrations among 
samples was accomplished using primers that amplify a fragment of 28s rRNA. One 
of tenth of the PCR products were separated electrophoretically on 2% agarose gels 
and stained with ethidium bromide. The results were documented by photographs 
under UV-light (table 7). 
 16
II.2 Detection of G-CSFR mRNA expression by Northern blot analysis 
Northern blot hybridization was performed to examine the mRNA levels of G-CSFR in 
nonhematopoietic tissues of normal rats. Total RNA was separated according to size 
in formamide/formaldehyde gels, transferred to positively charged nylon filters and 
hybridized using the labeled ssDNA probe. All aqueous solutions were prepared with 
0.1% diethylprocarbonate (DEPC)-treated water. 
The basic steps in northern analysis include: 
− Isolation of total RNA (table 6)  
− Separation of RNA according to size in a denaturing agarose gel (table 17) 
− Transfer of the RNA to a nylon membrane (table 18) 
− Fixation of the RNA to the membrane (table 18) 
− Hybridization of probes (table 19) 
− Documentation of the results (table 20) 
II.3 Detection of the anatomic localization of G-CSFR mRNA by FISH 
FISH procedures were performed on slides from paraffin embedded samples of six 
normal Lewis rats (table 21). Negative controls for FISH include hybridization of the 
same tissue with a sense probe.  
Slides were observed using a fluorescent microscope (OLYMPUS BX60). The images 
were taken using a VYSIS CCD camera and transferred to a Macintosh computer 
using Smart Capture ® (Digital Scientific, Cambridge/ UK).  
II. 4 Detection of the anatomic localization of G-CSFR protein by IHC 
IHC was carried out on slides from paraffin embedded tissues (table 22). Anti-G-
CSFR antibody was an affinity purified rabbit polyclonal antibody raised against a 
peptide mapping to the amino terminus of G-CSFR (Santa Cruz, CA) of mouse origin 
cross reacting with rat and human G-CSFR.   
Purified antibodies from non-immunized rabbits were used as negative control.  
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Results were recorded according to the intensity of staining and the distribution in 
tissues. Images were taken using a a digital camera (Nikon CoolPix 995) mounted to 
a microscope (OLYMPUS BX50).  
III. Regulation of G-CSFR protein expression in nonhematopoietic organs  by G-
CSF treatment and 90% partial hepatectomy in rats 
 III.1 G-CSF administration and partial hepatectomy  
III.2 Immunohistochemical staining and analysis 
 
III.1 G-CSF administration and partial hepatectomy   
Five rats were treated G-CSF (rh-G-CSF, Neupogen, Germany) at doses of 
100µg/kg/day subcutaneously for five days prior to sacrifice.  
 
90% partial hepatectomies (PH) were performed in 30 rats according to the technique 
described by Higgin’s (Higgins, 1931). Half of the animals in each group received G-
CSF at doses of 100µg/kg/day subcutaneously starting five days prior to the liver 
resection until sacrifice. Animals were sacrificed at three time points (6h, 24h, 7d) 
after the operation (for group distribution see table 23).  
A full autopsy was performed. Samples of heart, lung, spleen, kidney, liver, small 
bowel, pancreas, lymph node and BM were taken and fixed in 10% buffered formalin.  
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Results: 
I. Probe development for G-CSFR 
I.1 Primer design for rat G-CSFR  
I.2 DNA and RNA extraction 
I.3 Amplify G-CSFR from DNA by PCR and from RNA by RT-PCR 
I.4 Sequencing 
I.5 Probe designing, synthesizing and labeling  
 
In the current study, a combined approach involving gene expression analysis of 
tissues and in situ Hybridization, as well as immunohistochemistry was carried out to 
study expression patterns of G-CSFR mRNA and protein, respectively. 
I.1 Primer design 
The sequence of murine and human G-CSFR is available in the Genbank database. 
Alignment of murine and human G-CSFR nucleotide sequence showed a 72.5% 
homology. Ten conserved regions were detected (table 4) Seven of them were used 
as templates for the primers. The remaining three were rejected due to their low GC 
content. Six pairs of primers were designed (list of primers see table 4). 
I.2 DNA and RNA extraction  
Genomic DNA was isolated and purified from rat liver and bone marrow. OD 260/280 
was in the range of 1.73 to 1.82; RNA was isolated from rat liver tissue, OD 260/280  
was in the range of  1.67 to 1.78.   
No degradation of DNA or RNA could be detected on the agarose gels. 
I.3 PCR and RT-PCR reaction 
Six different primer sets were used to amplify parts of the G-CSFR by Touch-down 
PCR using DNA and by RT-PCR using total RNA.  
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When the length of 6 RT-PCR and 6 PCR products were compared, only the first pair 
of primers produced an amplicon that was close to the predicted length, and the 
product showed a single band on agarose gel. (table 24)  
Gene structure was shown in figure 1A. 
With the forward primer (5’- TGA GCT CTG CGGG CTCC), and the reverse primer 
(antisense 3’-GAC TCC ATG CCA TGG CCC), an amplicon with a length of 500 
nucleotides was generated. Since this part maps to the putative signal binding region 
of the human G-CSFR and parts of this sequence are specific for the G-CSFR, as 
shown by sequential analysis of the Sequence using BLAST (NCBI).  
I.4 Sequencing 
The sequencing results of the amplicon showed a 350nt readable fragment, 150nt 
shorter than expected from the length of the PCR product. The full sequence of the 
amplicon was only readable after cloning the amplicon and transforming it into DH5α 
and then using plasmid DNA. The DNA sequences of G-CSFR are shown in figure 
1B.  
Sequencing results were compared with the database EMBL/Genbank/DDJB. This 
fragment was 72% homologous with the extracellular domain of human G-CSFR from 
1058 to 1506, containing an additional 50 bases. Compared to mouse G-CSFR, a 
75% homology was demonstrated. The sequence maps to the mouse gene starting at 
1062 and ending at the 1511. (figure 1B) 
I.5 Probe generation and labeling 
According to the guidelines of probe design, a 300bp region was determined as 
probe. A new set of primer was designed for PCR.  
With the forward primer (5’-ACG GGA TCC GTG AGA CGC), and the reverse primer 
(5’- CTT CTC AAT TAC CAG CGA TGG), a 280nt ssDNA amplicon was synthesized 
by asymmetric PCR. Comparing the efficiency of the PCR reaction using unlabeled  
nucleotides, Fluorescin-12-dUTP and aminoallyl-dUTP (figure 2A). 
It showed an, at least, hundred-fold higher 
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efficiency of the PCR reaction using unlabeled nucleotides or 
aminoallyl-dUTP compared to Fluorescin-12-dUTP. 
II. G-CSFR distribution in normal rats 
II.1 Amplification of G-CSFR gene by RT-PCR 
II.2 Detection of G-CSFR mRNA expression by Northern blot analysis 
II.3 Detection of the anatomic localization of G-CSFR mRNA by FISH  
II.4 Detection of the anatomic localization of G-CSFR protein by IHC  
II.1 Amplification of the G-CSFR gene by RT-PCR 
II.1.1 RNA Isolation 
RNA isolated from rat tissues showed discrete bands of high molecular weight RNA 
between 7 kb and 15 kb in size, (composed of mRNA’s and hnRNA’s) two 
predominant ribosome RNA bands at ~5 kb (28s) and at ~2kb (18s), and low 
molecular weight RNA between 0.1 and 0.3 kb (tRNA, 5s). The isolated RNA had an 
A260/A280 ratio range from 1.75 to 1.89 when diluted in TE. No signs of degradation 
could be detected. (figure 2B)  
 
II.1.2 RT-PCR 
Total RNA was reverse transcribed and amplified by PCR. Using agarose gels it 
could be demonstrated that the amplicon had a size of 280 bp.  
G-CSFR mRNA was detected in all tested tissues (figure 2C).  
II.2 Detection of G-CSFR mRNA expression by Northern blot analysis 
In Northern blots a band of about 3kb was detected after hybridization in all tested 
samples (figure 2D). A high expression level could be found in the bone marrow and 
in the spleen.  
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II.3 Detection of the anatomic localization of G-CSFR mRNA by FISH  
Fluorescent in situ hybridization was performed to examine the cellular distribution of 
mRNA encoding the receptor.  
The mRNA for G-CSFR was detected in the cytoplasm of cells. 
Endothelial cells of arteries and veins and neurons consistently expressed G-CSFR 
mRNA in every organ. Fibroblasts and smooth muscle cells showed G-CSFR mRNA 
only in a very low number of cells.  
Parenchymal cells demonstrated various expression patterns (table 25): 
Liver  
G-CSFR mRNA was detected in single hepatocytes in zone 2 and 3 (figure 3A) 
The biliary epithelial cells were negative for G-CSFR mRNA.  
Heart 
G-CSFR mRNA was detected in most cardiac myocytes (figure 3B) 
Lung 
Expression of G-CSFR mRNA was not evident in cylinder cells of the respiratory tract. 
However mRNA expression could be detected in most type II pneumocytes (figure 
3C) 
Kidney  
G-CSFR mRNA was present in all epithelial cells of the proximal convoluted tubule. 
There was a significant decrease in the numbers of tubular cells that express G-CSF 
mRNA as the ducts descend. Only single urothelial cells of the renal pelvis showed a 
positive signal. Glomerular cells were negative. (figure 3D) 
Intestine 
G-CSFR mRNA was evident in single mucosal epithelial cells, mostly located at the 
base of crypts (figure 3E). 
Pancreas 
Most acinar cells expressed G-CSFR mRNA. Pancreatic ductular epithelial cells and 
islet cells were negative (figure 3F). 
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 Spleen  
In the white pulp of the spleen a few cells showed G-CSFR mRNA expression (figure 
3.G). 
Lymph node  
Single cells expressing G-CSFR mRNA were detected in lymphatic follicles (figure 
3H).  
BM 
Myeloid precursor cells showed positive staining. Erythrocytes and megakaryocytes 
did not show G-CSFR mRNA expression, whereas most of the polymorpho-
nucleocyte (PMN) population demonstrated a positive signal.  
II. 4 Detection of the anatomic localization of G-CSFR protein by IHC  
In immunohistochemistry, positive staining was also observed in the cytoplasm. 
Endothelial cells of arteries, veins and neurons consistently showed a positive 
staining. Fibroblasts and smooth muscle cells did not show a positive staining.  
Parenchymal cells demonstrated various staining patterns (table 26): 
Liver 
Rare hepatocytes in zone 2 and 3 showed an intense positive staining.  
Morphologically  they were indistinguishable from the surrounding hepatocytes that 
were not stained. Only a small number of biliary epithelial cells showed a faint positive 
staining. Trace levels of G-CSFR staining could be observed in the majority of Kupffer 
cells. (figure 4A) 
Heart 
Myocytes showed slight and a few myocytes moderate anti-G-CSFR immunostaining  
(figure 5A).    
Lung 
Cylinder cells of the respiratory tract showed a faint positive staining. Type 2 
pneumocytes were also weakly positive (figure 6A). 
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Kidney 
The tubular epithelial cells, both of the convoluted portion and the straight portion of 
proximal tubules, showed slight staining. In collecting ducts, there was a decrease in 
the intensity of G-CSFR staining in the epithelial as the ducts descend (figure 7A). 
Intestine 
Single epithelial cells showed positive staining. The staining was found only in the 
apical parts of the cytoplasm. Positive cells were found more often at the base of the 
intestinal crypts (figure 8A). 
Pancreas 
Most acinar cells showed a moderate to low positive staining. Islet cells showed no 
pronounced staining (figure 9A) 
Pancreatic ductular epithelial cells showed a slight positive staining in a low number 
of cells in small ducts and a slightly increasing number of cells, some of them also 
showing a little higher intensity of the staining in larger ducts. 
 
III. Regulation of G-CSFR protein expression in nonhematopoietic organs of G-
CSF treated and/or 90% hepatectomized rats  
III.2 Immunohistochemical analysis 
In IHC positive staining was observed in the cytoplasm. 
Endothelial cells of arteries, veins and neurons consistently showed a positive 
staining. The intensity of the staining was increased in all experimental groups in 
comparison to normal rats. Fibroblasts and smooth muscle cells did not show a 
positive staining.  
Parenchymal cells demonstrated various staining patterns (table 26) 
Liver  
After 90%PH, an increased number of mainly periportal and pericentral hepatocytes, 
some of them forming small groups showed a high positive staining at 6 hours, with 
slightly higher cell number at 24 hours. On day 7, the staining was approaching the 
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level observed in normal animals. Only a small number of biliary epithelial cells 
showed a faint positive staining. (figure 4B-D) 
In G-CSF-treated rats, the number of hepatocytes showing a high level of cytoplasmic 
staining increased a little and the other hepatocytes showed a faint positivity. (figure 
4E) 
After 90%PH and G-CSF treatment nearly all hepatocytes showed a strong positive 
staining after 6 hours. The number hepatocytes demonstrating a strong positivity 
decreased at 24 hours and 7days. (figure 4.F-H) 
The expression of G-CSFR on biliary epithelial cells was slightly induced by G-CSF 
administration. (figure 4G-insert) 
Heart  
In the 90% PH group, myocytes showed a intense staining at 6 hours, gradually 
decreasing to nearly the level found in normal animals until 7 days. (figure 5.B-D) 
In the G-CSF treated group, myocytes showed a moderate and some of them a high 
intensity of the staining. (figure 5E).  
After 90%PH and G-CSF treatment myocytes showed an intense staining at 6 hours 
gradually decreasing at 24 hours and 7 days, but showing a higher level than 
myocytes after PH only. (figure 5 F-H)  
Lung  
In the 90%PH group, slight G-CSFR staining was detected in the apical part of the 
cylinder cells of the respiratory tract and in type 2 pneumocytes at 6 hours, 24 hours 
and 7 days. (figure 6B-D) 
In G-CSF treated animals, the apical part of the cylinder cells of the respiratory tract 
and in type 2 pneumocytes showed a moderate positivity for G-CSFR. (figure 6E) 
In 90%PH with G-CSF treatment animals showed a slight increase in the intensity of 
the stain compared with G-CSF treatment only at 6 hours, decreasing at 24 hours and 
7 days (figure 6F-H)  
Kidney 
In the 90%PH group an increased positivity of tubular epithelial cells could be 
observed. (figure 7B-D) 
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In the G-CSF treated group single cells in the mesangium showed a weak positivity. 
Tubular epithelial cells showed an increased positivity compared to normal animals. 
(figure 7E) 
In 90%PH with G-CSF treatment animals the proximal tubular cells showed strong 
positivity until 7 days. The epithelial cells of distal convoluted tubules showed strong 
staining at 6 and 24 hours decreasing at 7 days (figure 7F - H).  
Intestine 
After 90% PH, medium intensity staining was found in nearly all of mucosal epithelial 
cells at 6 hours.  The staining showed an apical orientation. The number of positive 
cells decreased at 24 hours and 7 days. (figure 8 B-D) 
In G-CSF treated rats an increased number of mucosal epithelial cells showed a 
positive staining compared to normal animals. (figure 8E) 
After 90% PH and G-CSF treatment, medium intensity staining was found in nearly all 
mucosal epithelial cells at 6 and 24 hours.  The staining showed an apical orientation. 
The number of positive cells decreased at 7 days. (figure 8F-H) 
Pancreas 
In 90% PH group, the acinar cells showed a strong staining at all time points. 
Pancreatic ductular epithelial cells showed a strong staining at 6 and 24 hour, 
decreasing at 7 days. There was also a transient slight positivity in islet cells. (figure 
9B-D) 
In the G-CSF-treated animals, acinar cells stained intensely positive for G-CSFR. The 
islet cells showed low positivity. (figure 9E) 
After 90%PH and G-CSF treatment, the acinar cells showed a strong staining at all 
time points. Pancreatic ductular epithelial cells showed a strong staining at 6 and 24 
hour, decreasing at 7 days. There was also a transient slight positivity in islet cells. 
(figure 9F-H) 
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Discussion 
Adult stem cells are not only a hot topic in science but they are entering generally 
available sources of information like CNN ( 2000). Therapeutic breakthroughs by the 
help of adult stem cells are reported in normal newspapers (Fagan, 2003). Stem cell 
mobilization by G-CSF treatment is an widely used procedure to mobilize stem cells 
prior to stem cell transplantation. Mobilizing stem cells by G-CSF also showed a 
positive effect on the myocardial regeneration after infarctions (Kuethe et al., 2004). 
In a rat model hepatocellular damage (CdCl2-damage:(Theocharis et al., 1998), 
thioacetamid damage (Theocharis et al., 1999): showed a delayed onset of 
proliferation. Administration of G-CSF led to an accelerated onset of proliferation. 
There were no indications given in these papers whether this is due to a direct effect 
of G-CSF on liver cells or due to immigrated bone marrow derived stem cells. 
Irrespective the underlying reason for the effect of G-CSF administration in these 
experiments- G-CSF acts by way of its receptor: G-CSFR. 
To reach a deeper understanding of G-CSFR, our first step was to demonstrate the 
distribution of the G-CSFR. We are working in the rat model. The first challenge was 
to obtain and whenever not available produce reagents to demonstrate G-CSFR in 
rats. 
I. Sequence and Probe 
Sequence of rat G-CSFR 
The sequence of rat G-CSFR has not been published. Conserved regions of G-CSFR 
were deducted from a comparison of mouse (Fukunaga et al., 1990a) and human 
(Fukunaga et al., 1990b) G-CSFR. We sequenced part of the extracellular domain of 
the rat G-CSFR gene, which contained the highly conserved motif “WSXWS” shared 
by members of the cytokine receptor family. Besides this a G-CSFR specific stretch 
was found. Specificity was shown by comparing this sequence with other known 
sequences using BLAST (NCBI). This part of the gene was included in the 
subsequent design of the G-CSFR probe. 
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Probe Generation 
Detection of G-CSFR mRNA expression is based on the binding of a specific probe. 
There are several types of probes currently used for the detection of RNA expression 
by hybridization-based techniques: RNA probes, double-strand DNA (dsDNA) probes 
and single-strand DNA (ssDNA) probes. 
To detect the G-CSFR expression at the mRNA level, we needed a highly specific, 
and stable probe which could be used in Northern blot hybridization and FISH. Tissue 
penetration should be good especially since cross-linking occurs during formalin 
fixation of the tissue, which makes tissue penetration more difficult. Background 
staining should be as low as possible and single stranded probes should be used to 
demonstrate that the positive staining result is really due to m-RNA expression and 
not just due to binding of the probe to DNA. 
RNA probes are still the most commonly employed since they were introduced by 
Casey and Davidson in 1977 (Casey and Davidson, 1977). They are synthesized by 
in vitro transcription (Melton et al., 1984). Even though the sensitivity of RNA probes 
is very high, their instability and poor tissue penetration limit their use (Bales et al., 
1993). 
The use of double stranded DNA probes was first reported by Taylor and his 
colleague (Taylor and Gettman, 1976). They can be produced by random priming 
(Holtke et al., 1990), PCR (Jansen and Ledley, 1989) or after cloning by plasmid 
production (Jacquet et al., 1977).   
ssDNA probes were first generated in 1990 (Scully et al., 1990). ssDNA are 
synthesized by asymmetric PCR. This PCR technique is based on unequal 
concentrations of the forward and reverse primers (Pagratis, 1996). At the end of the 
PCR reaction, the amount of the sense or antisense strand - depending on the primer 
used at higher concentrations - of the amplified DNA is three to five times higher. The 
asymmetric amplification initially proceeds at an exponential rate and then slows to an 
arithmetic rate when the amount of one oligonucleotide primer becomes the limiting 
factor. Setting up multiple reactions can help to compensate for the decrease in total 
yield in a single reaction (Finckh et al., 1991).  
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Taking all this into consideration the use of ssDNA probes for the detection of G-
CSFR mRNA expression was the only logical choice. 
 
A probe is useless unless it is labeled. The sensitivity of a probe depends to a great 
deal on the attached label itself and the amount of label attached. 
Radioactive labeled nucleotides were the first labels used (Feinberg and Vogelstein, 
1983) and are still widely used. Their advantage is the high sensitivity. Their 
disadvantage is due to their radioactivity that can be only handled in special 
laboratories under special security precautions. 
The revolution in nucleic acid labeling was fueled by the wide assortment of new and 
improved nonisotopic marker molecules. The first molecule used was fluorescein, 
visualized via fluorescence (Martin et al., 1990). Nowadays multiple fluorochromes 
are available. These fluorescent labels now offer sensitivity levels similar to those 
produced by radioisotopes, but without the high backgrounds originally observed 
(Dirks et al., 1991) . In addition they allow the simultaneous analysis of multiple 
probes. 
Enzymes like alkaline phosphatse and peroxidase can be used as labels. Their  
downside is that sensitivity is lower compared to  fluorochromes.  
Lately luminophores have been used. They show high sensitivity but in in situ 
hybridization they cannot be used since their ability to emit light is limited to very quite 
intervals that are not long enough to screen a slide. 
The use of nonradioactive labeles was a prerequisite for us. Fluorochromes seemed 
to be the appropriate label since we wanted to generate an ssDNA probe showing the 
highest sensitivity possible in in situ hybridization.  
Fluorochromes are either directly labeled to nucleotides which are used to label a 
probe. Another approach makes use of nucleotides which are labeled with a hapten 
like biotin or carry a chemically active group like aminoallyl-dUTP to which 
fluorochromes are attached in a subsequent reaction after the nucleotides were 
inserted into a probe.  Actually the first nonradioactive nucleic acid labeling method 
developed was based on the biotin-avidin/streptavidin complex (biotin-dUTP) (Langer 
et al., 1981).  But this method is based on a high affinity binding reaction of avidin and  
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biotin that can be the source of unspecific staining since biotin is also present in the 
tissue itself. 
The efficiency of a PCR reaction is defined as the amount of amplicon of expected 
size produced during a defined number of PCR cycles. We compared the use of 
Fluorescin-12-dUTP and aminoallyl-dUTP in PCR and found an at least hundredfold 
higher efficiency using aminoallyl-dUTP compared to Fluorescin-12-dUTP. 
Fluorescin-labeled dNTPs/NTPs can not be incorporated by reverse transcriptase or 
polymerases with the same efficiency as unlabeled NTPs, leading to variable 
incorporation efficiency of different dyes (e.g. FITC-NTP vs. Cy3-NTP) (Gauthier et 
al., 2002).  Aminoallyl-dUTP showed an efficiency that was on the same level as 
dTTP. So this chemically modified nucleotide seems not to influence the efficiency of 
the PCR.  
In addition amino-allyl dUTP is very stable, there is no loss due to exposure to light or 
high temperature. So both of the amino-allyl dUTP and the amino-allyl coupled DNA 
by PCR can be stored for a long time, and be coupled with dye before use.  
To the best of our knowledge, no procedure describing the application of two-step 
labeling method to label ssDNA probes was available at the time the dissertation 
started.  
II. G-CSFR Expression  
Saturable high-affinity receptors for G-CSF on human cells, including hematopoietic 
cells of granulocytic lineage, platelets, monocytes, and lymphocytes were 
demonstrated by biologically active, radioiodinated G-CSF (Larsen et al., 1990). In 
1990 murine and human G-CSFR were cloned (Fukunaga et al., 1990a; Fukunaga et 
al., 1990b).  
Based on the published sequence detection of mRNA expression by RT-PCR, 
Northern Blotting and in-situ hybridization was possible (Avalos et al., 1990; 
Bocchietto et al., 1993; Tweardy et al., 1992). In addition antibodies against G-CSFR 
protein are now available from commercial sources (Santa Cruz, CA). 
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We employed different methods to detect G-CSFR mRNA in rat tissues. To 
demonstrate expression of mRNA, RT-PCR was used as the most sensitive tool. 
Quantitatively mRNA expression was demonstrated by Northern blots.  
In all tissues we examined, G-CSFR mRNA were detected by RT-PCR and in 
Northern Blots. In both methods purified total mRNA is the basis of the tests. This is 
consistent with the results of Calhoun et al. who observed G-CSFR expression by in 
situ RT-PCR in nearly every organ and tissue examined in human fetus (Calhoun et 
al., 1999). What limits the interpretation of data acquired through these methods is 
the fact that the cellular distribution is not known and the mRNA detected could be as 
well transcribed by bone marrow derived cells located in the tissue. 
To demonstrate tissue distribution of mRNA transcription we employed FISH. These 
data were confirmed demonstrating protein expression by immunohistochemistry. 
Tissue expression was only regarded positive when mRNA and protein expression 
could be shown.  
It was reported that G-CSF administration modulates the expression of its receptor 
due to transcriptional activation without synthesis of new protein in mouse (Steinman 
and Tweardy, 1994). Tsuruta also demonstrated an induction of the expression of G-
CSFR mRNA by G-CSF in human neutrophils (Tsuruta et al., 1996). To look at the 
regulation of G-CSFR expression by way of this autocrine loop we used systemic 
administration of G-CSF in our rat model. 
G-CSF belongs to the group of cytokines. Cytokines very often form interwoven 
networks affecting each other. Major surgical trauma such as 90% liver resection is a 
well-defined animal model putting major stress on the organism thereby inducing 
multiple cytokines and growth factors. We wanted to test whether this “stress” by itself 
has an effect on the G-CSFR expression and whether there is an additive effect to the 
systemic G-CSF administration. Changes in the expression of G-CSFR due to 
administration of G-CSF and partial hepatectomy were demonstrated by 
immunohistochemistry 
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Heart 
G-CSFR could be detected in myocytes. Protein expression was upregulated by 
systemic administration of G-CSF and by 90% PH. The additive effect was shown 
more dramatic at 6 hours.   
Cardiac myocytes have been considered as terminally differentiated cells. It has been 
reported recently that mobilization of bone marrow stem cells by G-CSF leads to 
regeneration and functional improvement after infarction (Kuethe et al., 2004; Norol et 
al., 2003). In papers looking at the beneficial effect of bone marrow derived stem cells 
after cardiac lesions a direct effect of G-CSF on myocytes has never been taken into 
consideration. Since the receptor was present in cardiomyocytes and the expression 
was upregulated by G-CSF administration, a direct effect seems possible. 
At the same time the pluripotentiality of adult hematopoietic stem cells has been 
challenged (Holden and Vogel, 2002; Wagers et al., 2002), and the process of 
transdifferentiation, used to explain how tissue-specific cells can generate cells of 
other tissues, is controversial (Terada et al., 2002; Ying et al., 2002).  
 
Lung 
Early studies revealed the presence of G-CSFR and its ligands in human fetal lung 
tissues (Calhoun et al., 1999). We found G-CSFR in type 2 pneumocytes in normal 
animals. A role of G-CSF and its receptor is also indicated by the fact that diffuse 
alveolar damage, is seen in knock out mice lacking G-CSFR (Seymour et al., 1997). 
In addition G-CSF was demonstrated to promote lung regeneration and increase 
bone marrow-derived cell numbers in alveoli (Ishizawa et al., 2004). We found that G-
CSF treatment stimulated G-CSFR expression in alveolar cells, and bronchiolar 
epithelium cells which could indicate an increased effect of G-CSF administration at 
this point. Whereas PH induced only a slight increase of G-CSFR expression, but 
there was also a marked additive effect of G-CSF administration and PH 
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Kidney 
In the current study, G-CSFR was detected in tubular epithelial cells. Both after G-
CSF treatment and in the 90% PH model we could demonstrate an increased 
expression in the tubular epithelial cells.  An additive effect could be demonstrated at 
6 hours and the subsequent decrease was shown. 
In a renal ischemia reperfusion model, Zhang showed that there is an increase in the 
serum concentrations of G-CSF protein, and in G-CSF mRNA and protein in the 
ischemic kidney (Zhang et al., 2004). So at least the production of the ligand could be 
demonstrated however no reports on G-CSFR expression in parenchymal cells of the 
kidney exist. Only in human fetus G-CSFR has been reported (Calhoun et al., 1999). 
 
Intestine 
In human fetus G-CSFR was demonstrate in enterocytes (Calhoun et al., 2000).  In 
normal rats, only a small number of enterocytes expressed G-CSFR. After G-CSF 
treatment, G-CSFR expression was distinctly enhanced in the apical part of the 
cytoplasm of the enterocytes. Also 90% PH induced marked G-CSFR expression at 6 
hours. In PH and GCSF treated animals, there was dramatic increase in the 
expression of G-CSFR at 6 hours, and slightly decreased expression at 7 days. 
 
Pancreas 
Although pancreatic carcinoma has been reported to produce G-CSF (Ohtsubo et al., 
1998; Uematsu et al., 1996) little has been determined about the receptor for G-CSF 
in either normal or tumor cells of pancreas.   
We demonstrated G-CSFR expression in acinar cells of the pancreas. Upregulation 
could be shown after G-CSF treatment and after 90%PH.G-CSF plus 90%PH also led 
to a induction of G-CSFR expression in islet cells. 
A beneficial effect of G-CSF treatment has recently been shown in a rat pancreatitis 
model (Cui and Bai, 2003) but has been attributed to the increase in bone marrow 
derived stem cells. 
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III. G-CSFR and liver regeneration 
Liver 
G-CSFR expression has been demonstrated in the human fetal liver (Calhoun et al., 
1999).  We found G-CSFR expression in a few hepatocytes in zone 2 and 3 in normal 
rats. While G-CSF treatment alone leads only to a minor increase in G-CEFR 
expression, 90%PH and especially 90%PH plus G-CSF treatment led to a marked 
increase in hepatocellular G-CSFR expression. 
Cytokines have been proposed as the earliest factors triggering activation of several 
transcription factors during liver regeneration (Diehl, 2000). G-CSFR is closely related 
to the IL-6R, and overlapping signal transduction pathways exist (Ziegler et al., 1993). 
It has been shown that G-CSF administration accelerates and enhances proliferation 
of hepatocytes after partial hepatectomy and chemical injury in rats (Theocharis et al., 
1996; Theocharis et al., 1997). Additionally, the administration of G-CSF to rats after 
chemical injury of the liver increased the biosynthesis and mitotic activity in 
hepatocytes. In normal rats, G-CSF administration did not increase mitotic activity in 
hepatocytes (Theocharis et al., 2003). This suggests that G-CSF does not by itself 
exert mitogenic action, in quiescent hepatocytes. However G-CSF enhances 
hepatocellular proliferation acting possibly like other cytokines, by modulating the 
expression of growth factors.  
At the same time it could be demonstrated that bone marrow derived stem cells 
migrate to the liver and transdifferentiate into hepatocytes (Petersen et al., 1999). 
This transdifferentiation has also been shown in other models (gender different liver 
or bone marrow transplantation) (Strain, 1999; Theise et al., 2000b). The frequency of 
transdifferentiated hepatocytes however is discussed quite controversial. Thus the 
biologic relevance remains doubtful. 
Especially after liver resection or chemically induced damage (Theocharis et al., 
1996; Theocharis et al., 1997). the positive effect of G-CSF administration could be 
on one hand due to increase in the number of peripheral stem cells. On the other 
hand the combination of G-CSF administration plus subtotal liver resection led to a 
marked increase in the expression of G-CSFR in the early phase after the operation. 
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Especially this phase is critical for the survival after extended PH and it could be 
speculated whether G-CSFR is an important signal transducer in hepatocyes. 
 
Further experimental data on the mechanism of action of exogenously administered 
G-CSF, as well as endogenously produces G-CSF, on the hepatocyte proliferative 
response to different kind of stimuli are necessary in order to delineate the 
mechanism of its action and to support the clinical significance of the administration of 
this growth factor in extensive liver injury. 
  
 
Conclusion: G-CSFR was expressed in specific cells of the liver and other major 
nonhematopoetic organs of the rats and was enhanced by either pretreatment with its 
ligand or a major surgical trauma such as 90% liver resection, which suggests that G-
CSF may play a role as early phase protein in the liver regeneration, and the 
beneficial effect may take advantage from the additive effect.  
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Tables  
Table 1. General reagents and materials 
Reagents Producer/Supplier Address 
10x MOPS Amresco Co. Solon, OHIO, USA 
20x SSC VYSIS Inc Downers Grove, IL, USA 
Boric Acid Carl Roth GmbH Karlsruhe, Germany 
Calcium Chloride Sigma Chemical Co. St Louis, MO, USA 
Chloroform Sigma Chemical Co. St Louis, MO, USA 
Diethaonolamine Sigma Chemical Co. St Louis, MO, USA 
Dimethyl Sulfoxide Amresco Co. Solon, OHIO, USA 
Ethanol  Mallikrodt Baker B. V  Deventer, Holland 
Ethidium Bromide Sigma St Louis, MO, USA 
Ethylene Diamine Tetraacetic Acid Amresco Co. Solon, OHIO, USA 
Glycerol Sigma Chemical Co. St Louis, MO, USA 
Hydrochloric acid Carl Roth GmbH Karlsruhe, Germany 
Immun-mount Shandon Pittsburg, PA, USA 
Isopropanol Sigma Chemical Co. St Louis, MO, USA 
Magnesium Chloride Amresco Co. Solon, OHIO, USA 
Methylene Blue Sigma  St Louis, MO, USA 
Paraformaldeyde Merck GmbH Hohenbrunn, Germany 
Peroxide hydrate Carl Roth GmbH Karlsruhe, Germany 
Phosphate Buffered Saline Sigma Chemical Co. St Louis, MO, USA 
Sodium Acetate Amresco Co. Solon, OHIO, USA 
Sodium Chloride Amresco Co. Solon, OHIO, USA 
Sodium Dodecyl Sulfate Amresco Co. Solon, OHIO, USA 
Sodium Hydroxide Amresco Co. Solon, OHIO, USA 
Tris (hydroxymethyl)-
aminomethane 
Carl Roth GmbH Karlsruhe, Germany 
Trypton/Pepton Serva Electrophoresis GmbH Heidelberg, Germany 
Xylol Mallckrodt Baker B.V.  Deventer, Holland 
Yeast Extract  Serva Electrophoresis GmbH Heidelberg, Germany 
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Table 2. General Equipments and Instruments 
Equipments Producer/Supplier Address 
ABI PRISM 310 Genetic 
Analyzer  
Perkin Elmer Applied 
Biosystem 
Foster City, CA, USA 
Biophotometer Eppendorf GmbH Hamburg, Germany 
CCD camera VYSIS Inc. DownersGrove, IL, USA 
Centrifuge 5415 D Eppendorf GmbH Hamburg, Germany 
Consort E132  Peqlab Biotech. GmbH Erlangen, Germany 
Digital camera Nikon CoolPix 
995 
Nikon Inc. Japan 
Electrophoresis tank Eppendorf GmbH Hamburg, Germany 
Fastprep FP120 Savant Inc. Holbrook, NY, USA 
Gerhardt Thermoshaker Peter Oehmen GmbH Essen, Germany 
GFL Water bath Gesellschaft fur Labortechnik 
GmbH 
Burgwedel, Germany 
Heraeus Biofuge Kendro Laboratory GmbH Hanau, Germany 
Heraeus Oven Kendro Laboratory GmbH Hanau, Germany 
Hybridization Oven UniEquip. GmbH Martinsried, Germany 
HYBrite VYSIS Inc. DownersGrove, IL 
USA 
Liebherr Refrigerator Liebherr GmbH Germany 
OLYMPUS BX50 light 
microscope 
Olympus Inc. Japan 
Omni Gene Primus thermal 
cycler 
MWG Biotech GmbH Ebersberg, Germany 
UV light Roth, GmbH Karlsruhe, Germany 
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Table 3. Principles of primer design  
Length: 18-30 nucleotides 
G/C content: 40-60% 
Tm: Estimate melting temperature (Tm) 
Tm=2C x (A+T)+4C x (G+C) 
Whenever possible, design primer pairs with similar Tm values. 
Optimal annealing temperatures may be above or below estimated Tm.  
As a starting point an annealing temperature was used 5ºC below Tm. 
Sequence: − Avoid complimentarity of two or three bases at the 3’ ends of 
primer pairs to reduce primer-dimer formation;  
− Avoid runs of 3 or more Gs or Cs at the 3’ end; avoid a 3’end T;  
− Avoid complementary sequences within a primer sequence and 
between the primer pair. 
 
 
 
Table 4.  Conserved regions and primers 
 Consensus 
position 
Leng-
th (nt) 
Consensus sequence Tm 
(°C) 
G/C 
% 
Modifie
d Tm 
(°C) 
1 609~627 19 TCTGCCAGTGGGAGCCAGG 63.2 68.4 59.5 
2 848~865 18 CCCATGGATGTTGTGAAA 51.7 44.4  
3 1063~1079 17 TGAGCTCTGCGGGCTCC 59.7 70.6 59.7 
4 1247~1267 21 GTGCAGCTGTTCTGGAAGCCA 62.4 57.1 59.6 
5 1494~1511 18 GACTCCATGCCATGGCCC 60.8 66.7 60.8 
6 1789~1803 15 GCTGCATCTAAAGCA 41.1 46.7  
7 1814~1836 23 ACCTGGGCACAGCTGGAGTGGGT 68.9 65.2 61.4 
8 1871~1891 21 ACCCACTACACCATCTTCTGG 55.2 52.4  
9 1960~1975 18 CCTGGAGCCCGCCAGT 59.3 75.0 59.3 
10 2584~2606 23 TGACTCCACTCAGCCCCTCTTGG 65.6 60.9 59.8 
Red color, modified nucleotides; gray color, conserved region not used for primer 
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Table 5. DNA purification protocol  
DNA purification kit QIAGEN, Hilden, Germany Reagents 
Proteinase K Roche, Mannheim, Germany 
Equipments Microfuge  
Procedures 
Homogeniza-
tion and 
lysis 
1. Cut tissues into small pieces, place them in a 1.5ml micro-centrifuge 
tube.  Add 180ul of Buffer labeled ATL. 
2. Add 20ul Proteinase K, mix with vortex, incubate at 56ºC on a 
heating  platform until complete lysis of tissue 3 hours. 
3. Briefly centrifuge the tube (800g 10sec), add 200 µl Buffer labeled 
AL, pulse-vortexing, mix 15sec, incubate at 70ºCfor 10min, briefly 
centrifuge again. 
Binding 4. Add 200ul of 100%ethanol, mix by pulse-vortexing 15sec, briefly 
centrifuge in a 1.5ml tube at 800rpm for 15sec. 
5.  Apply the mixture to a spin column, centrifuge at 6000g (8000rpm) 
1min. 
Washing 6.  Add 500ul Buffer AW1, centrifuge at 6000 g (8000rpm) 1min, put the 
spin column on a clean 2ml collection tube. 
7.  Add 500ul Buffer AW2, centrifuge at 12000 g (14000rpm) for 3min. 
Elution 8.  Place spin column on a 1.5ml microcentrifuge tube, add 200 µl Buffer  
labeled AE or distilled water, incubate at room temperature for 1-5 
min, centrifuge at 6000 g (8000rpmm) min. 
9. Repeat incubation and centrifugation. A third elution step using 200 µl 
Buffer labeled AE increased yield. 
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Table 6.  RNA purification protocol 
RNeasy RNA extraction kit QIAGEN GmbH, Hilden, Gemany Reagents 
DNase kit QIAGEN GmbH, Hilden, Gemany 
Equipments Microfuge 
Procedures 
Homogeniza-
tion and 
lysis 
1. Remove stabilized tissue from reagent using forceps. 
2. Place sample into 600µl Buffer labeled RLT. 
3. Disrupt and homogenize with a pestle-mortar in 1.5ml tube, until 
uniformly 
Binding 4. Centrifuge the tissue lysate for 3min at 16,1000rpm in a 1.5ml tube 
in microcentrifuge.  
5. Carefully transfer the supernant to a new microcentrifuge tube with a  
pipett.  
6. Add 600ul of 70% ethanol to the lysate, mix immediately by 
pipetting. 
Washing 7. Apply 700µl sample (including any precipitate) to a RNeasy column, 
place on a 2 ml collection tube, centrifuge for 15 sec at 8000 g, 
discard the flow-through.  
8. Add 350µl Buffer labeled RW1 to the RNeasy column, centrifuge 
15sec at 8000 g to wash the column, discard the flow-through.   
On column 
DNase 
Digestion  
9. Add 10µl DNase I stock solution and 70ul buffer labeled RDD 
mixture onto the column and place on benchtop 30ºC for 15 min. 
10. Pipet 350µl Buffer RW1 to the RNeasy column, centrifuge 15sec at 
8000 g to wash the column, discard the flow-through.   
11. Add 500µl buffer RPE onto the column, centrifuge at 8000g 
(10000rpm) for 15sec to wash the column. (Reuse the collection 
tube) Repeat again. 
Elution 12. Transfer RNeasy column on a new 1.5ml collection tube, pipette 30- 
      50µl RNase-free water directly onto RNeasy silica-gel membrane,  
      centrifuge for1min at 8000 g to elute.. 
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Table 7. Electrophoresis Analysis 
5x TBE MBI Fermenta 
Marker DNA MBI Fermenta 
Reagents 
6x loading dye solution MBI Fermenta 
Equipment electrophoresis tank 
Procedures 
Gel 
preparation 
1. Prepare electrophoresis buffer (0.5 x TBE) to fill in the electrophoresis 
tank. 
2. Add 1g agarose powder per 100ml (1%) electrophoresis buffer in an 
glass bottle.  
3. Heat the bottle in a microwave until the agarose dissolves.  
4. Cool the solution to 60ºC (roughly). During this time, place a comb 
(0.5mm) above the plate so that a complete well is formed when the 
agarose is added.  
5. Pour warm agarose solution into the plastic tray.  
6. After the gel was completely solidified (45min at room temperature), 
carefully remove the comb and mount the gel in the electrophoresis 
tank. 
Loading 
samples 
7. Mix the samples of DNA 5µl with the 6x gel-loading dye buffer 1.5µl. 
8. Add just enough electrophoresis buffer to cover the gel to a depth of 
about 1mm. 
9. Load 6µl of the sample mixture into the slots of the submerged gel 
using a pipette. 
Running 
gel and 
dying 
10. Close the lid of the gel tank and attach the electrical leads so that the 
DNA will migrate toward the anode. Apply a voltage of 100V (5V/cm). 
Run the gel until the bromophenol blue has migrated at the end of the 
gel. 
11. Turn off the electric current and remove the leads from the gel tank.   
12.  Stain the gel by soaking it in solution of ethidium bromide (0.5µg/ml) 
for  30-45 min at room temperature. 
13.  Examine the gel by ultraviolet light and take a photograph of the gel. 
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Table 8. PCR reaction protocol 
10 x PCR buffer QIAGEN, Hilden, Germany 
dNTP (mix) QIAGEN, Hilden, Germany 
MgCl2 QIAGEN, Hilden, Germany 
HotstarTaq QIAGEN, Hilden, Germany 
Reagents 
Primer synthesized by MWG, Ebersberg, Germany 
Equipments Thermal cycler 
Procedures 
PCR recipe PCR reagents Volume Final concentration 
Template                   1 µl ~100ng DNA 
Primer F,R                 2 µl 400pmol/ µl 
dNTP mix                   2 µl 200uM each 
10x PCR buffer          5 µl 1x 
MgCl2                         2 µl 2µM 
HotStarTaq               0.25 µl 1.25U/reaction 
Total volume 50 µl  
 
PCR program  Temperature Time Number of cycles 
Initial 
denaturation 
95ºC 15min 1(first) cycle 
Denaturation 95ºC 30sec 
Annealing 66ºCx2, 
64ºCx2, 
62ºCx2, 
60ºCx2, 
58ºCx2, 
56ºCx2, 
54ºCx28 
 
30 sec 
Elongation 72ºC 1min 
 
 
40 cycles 
Final 
elongation 
72ºC 10min 
Totaltime 35 circles 2h 38min     
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Table 9. Two-step RT-PCR Protocol 
Random primer Promega, USA 
dNTP mixure QIAGEN, Germany 
RNase inhibitor MBI Fermentas, Germany 
5x Reaction Buffer Roche,Germany 
Reagents 
M-MuLV Reverse Transciptase MBI Fermentas, Germany 
Methods Two-step RT-PCR 
Synthesis 
of the first 
strand of 
cDNA 
Reagents Volume Final concentration 
Template RNA  1.5µl           (0.1-5µg) 
Random primer    1µl             2.5uM       
Final elongation                                        72°C                          10min   
Deionized water  8.5µl           to 11µl 
1. Incubate the mix at 70ºC for 5 min and chill on ice. Add the reagents in the 
following order:  
5x reaction Buffer  4µl           1x
Initial denaturation                                     95°C                        10min
10mM dNTP mix  2µl           1.0mM each 
RNase inhibitor  1µl           1U/µl 
Deionized water  1µl to 19µl 
2. Incubate at 25ºC for 5 min. 
M-MLV reverse transcriptase (10U/µl). 1µl                 200 units            
Total time (35 cycles)                                                                   2h 38min                   
3. Incubate the reaction mixture at 25ºC for 10min and then at 42ºC for 60min 
  4. Stop the reaction by heating at 72ºC for 10min. Chill on ice. 
PCR 
amplification 
Reagents Volume    Final concentration
Denaturation during cycles                    95°C                         30sec                
10x PCR buffer (containing 15mM MgCl2)    5µl 1x 
dNTPs (10mM)                                               1µl 0.2mM each 
Primer F/R (10pmol/µl)    2 µl 0.4µM 
Template cDNA from last step 2.5µl  
TaqDNA polymerase (5U/µl)   0.25ul         1.25U 
Primer annealing                                       58°C                         30sec                       
Steps                                                  Temperature         Duration   
Sterile H2O  q.s.
Extention           72°C      30sec  
 
Total volume                                                 50µl  
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Table 10. PCR product purification protocol 
Reagents QIAquick Purification Kit QIAGEN, Hilden, Germany 
Equipments Centrifuge 
Procedures 
Binding DNA 1. Mix PCR product from the same primer in a QIAquick spin column. 
2. Add 5 volumes of buffer labeled PB to 1 volume of PCR reaction 
and mix. 
3. Place the spin column on a provided 2-ml collection tube and 
centrifuge 60 sec at 12,000g. 
4. Discard flow-through. Place QIAquick column back onto the same 
tube. 
Washing 5. Add 0.6ml buffer PE to column and centrifuge 60 sec at 12,000g .  
6. Discard flow-through. Place QIAquick column back onto the same 
tube.  Centrifuge another 60 sec at 13200g.  
7. Place QIAquick column in a clean 1.5-ml microfuge tube. 
Eluting DNA 8. Add 30µl buffer labeled EB or 50µl H2O to the center of the 
QIAquick column and  centrifuge for1min at 13200g after incubation 
at room temperature for 1 min. 
9. Store DNA at –20°C. 
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Table 11. Cycle Sequencing Reaction Protocol 
Reagents BigDye Terminator Ready Reaction  Perkin Elmer, Foster City, CA 
 Template Suppression reagent Perkin Elmer, Foster City, CA 
Equipments Microfuge, ABI PRISM 310 Genetic Analyzer, thermal cycler 
Procedures  
Cycle 
sequencing 
1. Prepare the reaction to an end volume of 20µl: Mix well and spin briefly. 
Reagents Final concentration  
Terminator Ready Reaction             25pmol (5µl) 
Template PCR product DNA            8ng 
Primer (For/ Rev)                              3.2pmol 
Denionized water                              q.s. 
          Total volume                                               20µl 
2. Cycle sequencing on thermal cycler: Repeat the following for 25 cycles:  
− Rapid thermal ramp to 96ºC(1ºC/sec), 96ºC for 10sec. 
− Rapid thermal ramp to 50ºC, 50ºC for 5sec. 
− Rapid thermal ramp to 60ºC, 60ºC for 4 min. 
Rapid thermal ramp to 4ºC and hold until ready to purity. 
Purifying 
extention 
products 
3.  Prepare precipitating mixture in a 1.5-ml tube including: 
    10µl of 0.3M sodium acetate (NaOAc), pH4.6      
    250µl of 95% ethanol (EtOH)                                
    80µl deionized H2O                                                            
4. Remove the product (20µl) to the precipitated mixture, mix thoroughly. 
5.  Vortex the tubes and leave at room temperature for 15min at least to 
precipitate the products.  
6. Spin the tubes in microcentrifuge for 20min at maximum speed 13,2000g. 
Proceed to the next step immediately. 
7. Carefully aspirate the supernatant with a pipette tip and discard. 
8. Rinse the pellet with 250µl of 70% ethanol (-20ºC). Mix them briefly. Vortex. 
9. Place the tubes in microfuge in the same orientation as in step 4. Spin for 
15min in microcentrifuge at maximum speed, aspirate supernatant, discard. 
10. Dry the pellet in dark with the lids open at room temperature for 1hour. 
Sample 
Electrophore
sis 
11. Add 20µl Template Suppression reagent to the dried sample pellet, vortex  
    and centrifuge briefly for several times to resuspend all the pellet.  
12. Incubate at 90ºC for 2 min in thermal cycler to denature. Then chill on ice  
    and place it on ice until ready to use. 
13. Load the samples 20µl (at least 15µl) in the Sequencing Analyzer system.  
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Table 12. Plasmid Transformation Protocol 
Reagents pCR4-TOPO Invitrogen, Carlsbad, CA, USA    
 EcoR I Invitrogen, Carlsbad, CA, USA 
Equipments Incubator, water bath, Thermal cycler 
Procedures 
Setting up 
TOPO Cloning 
Reaction 
 
1. Prepare fresh PCR products as indicated above. 
2. Purify PCR product as indicated above. 
3. Mix 2µl PCR product with 1µl salt solution, 1µl TOPO vector and 2µl sterile 
water, incubate for 5min at room temperature (22-23ºC). 
4. Place the reaction on ice. 
Transforming 
One Shot 
Competent 
Cells 
       5.    Thaw on ice 1 vial of One Shot cells for each transformation.  
6.    Add 2µl of TOPO cloning reaction into a vial of E.coli and mix gently. 
Incubate on ice for 5min. 
7. Heat-shock the cells for 30 sec at 42ºC without shaking. 
8. Immediately transfer the tubes to ice. Add 250µl SOC medium. 
9. Shake the tube horizontally (200rpm) at 37ºC for 1h. 
10. Spread 50µl from each transformation on a prewarmed agarose plate 
containing Penicillin (100ug/ml) and incubate over night at 37ºC.  
11. An efficient TOPO Cloning Reaction should produce hundreds of colonies. 
Pick ~10 colonies for analysis. 
Restricted 
digestion 
12. Prepare an enzyme digestion reaction, Incubate at 37ºC for 1 hour. 
Reagents Volume Concentration 
EcoR I (50U/µl)   0.5µl 25U/reaction 
10x Buffer      2µl 1x 
Plasmid sample      5µl  
Deionized water 12.5µl  
            Total volume                       20µl 
13. Analyze the digested fragments on 0.7% agarose gel.  
Analyzing 
transformants 
by PCR 
14. Prepare a 20µl PCR cocktail consisting of PCR buffer, dNTPs, primers, 
and Taq polymerase according to recipe indicated above.  
16.   Pick 10 colonies and resuspend individually in 20µl of the PCR cocktail. 
17.   Incubate for 10min at 94ºC to lyse the cells and inactivate nucleases. 
18. Amplify for 20~30 cycles (94ºC for 1min, 55ºC for 1min, and 72ºC for 
1min).  For final extention, incubate at 72ºC for 10min. Hold at 4ºC. 
19. Visualize by agarose gel electrophoresis. 
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Table 13. Purifying of plasmid protocol 
Reagents QIAGEN Plasmid Purification Kit QIAGEN, Hilden, Germany 
Equipment Microfuge, shaker 
Methods Modified Alkaline Lysis Method 
Procedures 
 Harvest  
cells 
1. Pick a single colony from a freshly streaked selective plate and 
inoculate a starter culture of 5ml LB medium containing ampicilin 
100µg/ml. Incubate for 8h at 37ºC with vigorous shaking (~300rpm). 
2. Dilute the starter culture1/500 into 25ml selective LB medium. Grow 
at 37°C for 16hours. 
3. Harvest bacterial cells by centrifugation at 6000g for 15min at 4ºC. 
 Alkaline   
lysis 
4. Resuspend the bacterial pellet in 4ml buffer labeled P1 by vortexing. 
5. Add 4ml buffer labeled P2, mix gently but thoroughly by inverting 4-6 
times, and incubate at room temperature for 5min, till the lysate 
appear viscous. 
6. Add 4ml chilled buffer labeled P3, mix immediately but gently by 
inverting 4-6 times, and incubate on ice for 15 min.  
 Binding 7. Centrifuge at 15000g for 30min at 4ºC. Remove supernatant.  
8. Re-centrifuge the supernant at 15,000g for 15min at 4ºC. Remove 
supernatant. 
 Washing 9. Equilibrate a QIAGEN-tip 100 by applying 4ml Buffer labeled QBT, 
and allow the column to empty by gravity flow. 
10. Apply the supernatant and allow it to enter the resin by gravity flow. 
11. Wash the tip with 2x10ml Buffer labeled QC. 
 Eluting 12. Elute DNA with 5ml buffer labeled QF, collect the eluate in a 10ml 
tube. 
13. Precipitate DNA by adding 3.5ml room-temperature isopropanol to 
DNA. Mix and centrifuge immediately at 15000g for 30min at 4ºC. 
14. Wash DNA pellet with 2ml 70% ethanol, and centrifuge at 15000g for 
10min. 
15. Air-dry the pellet for 5-10min, and redissolve the DNA in 100µl of TE 
buffer. 
 47
Table 14.  Aminoallyl-dUTP incorporation protocol 
allylamine-dUTP  Sigma, St. Louis, MO, USA 
dNTP (individually) Molecular Probes, Eugene, OR, USA 
Reagents 
Other PCR reagents Same as touchdown PCR 
Methods Two-step amine-modified dUTP incorporation method  
Procedures 
Incorporate 
Direct 
Fluor-dUTP 
by PCR 
1. Dilute primer 1/100 with distilled water further to final concentration 0.1uM 
irrespectively. Then mix F+R/100 or F/100+R. 
2.Set up Fluor-dUTP-PCR reaction mixture (100µl): 
Reagents Volume Final concentration 
10xBuffer (with 15mM MgCl2)                 10µl 1mM 
25mM MgCl2 10µl 4mM 
Fluorescein labeling dNTP mix             10µl 0.2mM dNTP 
Taq polymerase (5U/µl)             1µl 5U/100µl reaction 
DNA template (plasmid DNA)   1µl  
Primer F (10µM) +R/100 (0.1µM)   4µl 0.2µM/0.002µM 
Primer F/100 (0.1µM) +R  (10µM)         4µl 0.002µM/0.2µM 
dH2O                         60µl  
Total 100µl  
 
Incorporate 
aminoallyl-
dUTP by 
asymmetric 
PCR 
2. Set up PCR reaction mixture.  
3. Carry out PCR reaction in thermal cycler: 
35cycles, primer annealing at 56C 30 sec,  
Reagents Volume Final concentration 
10xBuffer (inc 15mM MgCl2)                 10µl 1x 
25mM MgCl2             10µl 2.5mM 
10 mM d(ACG)TP                    2µl 0.2mM 
5 mM dTTP 1.4µl 0.07mM 
10mM Aminoallyl dUTP  1.4µl 0.13mM 
Taq polymerase  (5U/µl)            1µl 5U/reaction 
DNA template (plasmid DNA)    3µl  
Primer F (10µM) +R/100 (0.1µM)    4µl 0.2µM/0.002µM 
Primer F/100 (0.1µM) +R  (10µM)          4µl 0.002µM/0.2µM 
BSA (10mg/ml)    4µl 0.4mM 
dH2O                          60µl  
TOTAL                     100µl  
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Table 15. Purification of amine-modified PCR product protocol 
Reagents QIAquick PCR purification Kit QIAGEN, Meinheim, Germany 
 Activated 5/6 Carboxyfluorescein emp Biotech, Berlin, Germany 
 Cy3 Monofunctional dye Amersham PharmaciaBiotech, 
Piscataway, UK 
Equipments Centrifuge 
Procedures: On-column purification method 
Purification of 
AMINE-
modified PCR 
product 
Protocol 
1. Add 100% ethanol 35ml in to purification kit buffer labeled PE. 
2. Add 5 volumes of buffer PB to 1 volume of PCR reaction and mix. 
3. Place the spin column in a provided 2-ml collection tube and centrifuge 60 
sec at10000g. 
4. Discard flow-through. Place QIAquick column back into the same tube. 
5. Add 0.6ml buffer labeled PE to the column and centrifuge 60 sec at full 
speed. Discard flow-through.  
6. Place QIAquick column back into the same tube. Repeat PE wash and 
centrifuge another 2 times 60 sec at 14000g. 
7. Place QIAquick column in a clean 1.5-ml microfuge tube. Add 50µl dH2O to 
the center of the QIAquick column and centrifuge for 1min at 13200g 
(16100rpm) after incubation in room temperature for 5min. 
Precipitation 8. Add 1/10 volume 3M NaOAc with 2 volume 100% Ethanol and mix them 
well. 
9. Freeze at –20ºC for 1hour and then centrifuge for 20~30min at full speed.  
10. Wash the pellet with 70% ethanol and allow it to air dry with lid open. 
Resuspension 11. Resuspend DNA-pellets by adding 1µg amine-modified DNA in 12µl 
distilled water.  
12. Mix it well. The solution could be warmed in 45ºC water bath for 2-3min if 
necessary 
Labeling with 
an Amino-
reactive 
Reaction 
13. Prepare one labeling reaction buffer: transfer 12µl prepared DNA solution 
to reaction vial. Transfer 4µl dissolved NaHCO3 into reaction vial.  
14. Add 10µl DMSO to Carboxyfluorescein derivates. Mix thoroughly by 
pipeting. 
15. Add 4µl mixture of dye (FITC or Cy3) and DMSO to reaction vial, mix them  
      carefully and gently. 
16. Leave the reaction in the dark at room temperature for 1 hour. 
17. Add glycine (pH8.0, 20mM final concentration) to stop the reaction. 
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Table 16. Probe purification protocol 
Cot-1 DNA Invitrogen, Carlsbad, CA, USA Reagents 
Salmon Sperm DNA Invitrogen, Carlsbad, CA, USA 
Methods On-column purification method 
Procedures 
Column 
hybridization 
Each of reaction should be purified on one column. 
1.    Gently tap the column to insure that the dry del has settled at the 
bottom of  the spin column. 
2. Remove the top column cap and reconstitute the column by adding 
0.65ml of water  
3. Allow at least 30min of RT hydration time before using the columns. 
Removal of 
Interstitial 
Fluid 
 
4. Place spin column into water collector. If the liquid on the column 
could not flow through spontaneously, cover the lid to add some 
pressure.  
5. Spin the column and C-6 in a centrifuge at 750 g for 2min.   
Sample 
Processing  
6. Transfer 20 to 50µl of sample to the top of the gel.  
7. Spin at 750g for 2min and collect the flow through in a 1.5ml tube 
9. Measure the quality and concentration of probe. 
Precipitation 10. Mix the following solution, vortex, precipitate at –20ºC overnight or 
at –70ºC for 1~2hours. 
labeled probe DNA 100ng    2µl  
Cot-1 DNA  2.5µg              2.5µl 
salmon sperm DNA              1µl  
3M NaAC                           0.5µl 
100% ethanol                      15µl  
12.  Centrifuge the precipitated DNA at 12000g at 4ºC for 30min. 
13. Carefully pour off supernatant, and place DNA pellet in a 56~60ºC 
heat block for 5~10min. 
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Table 17. Separation of RNA according to size for Northern blot analysis 
Formadehyde Sigma, St. Louis MO, USA Reagents 
Formamide Sigma, St. Louis MO, USA 
Equipments Consort gel box, shaker 
Procedures 
Separation 
RNA 
accrding to 
size 
1. Set up the denaturation reaction. Mix:  
RNA (up to 20µg)                    2.0µl           <1µg/µl 
10x MOPS buffer                    2.0µl            1x 
formaldehyde                          4.0µl           2.5M 
formamide                             10.0µl           50% 
ethidium bromide (200µg/ml)  1.0µl          10µg/ml 
2. Close the tubes, and incubate the RNA solution at 55ºC for 60min (or 
85ºC 10min). Chill the samples for 10min on ice, then spin 5sec. 
3. Add 2µl of 10x loading buffer to the samples placed on ice.  
4. Install the gel in a horizontal electrophoresis box (thickness should not 
exceed 6mm). Add sufficient 1x MOPS running buffer.   
5. Run the gel submerged in 1x MOPS buffer at 4~5V/cm until the 
bromophenol blue has migrated 2/3 (~8cm) for 3hours. 
6. Visualize the RNAs by placing the gel on a piece of Saran wrap on a 
UV transilluminator.  
7. Proceed with immobilization of RNA onto a solid support by capillary 
transfer. 
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Table 18. RNA transferring and fixing protocol 
Reagents Hybond-N+ membrane Amersham Phamacia Biotech Inc, Uppsala, 
Sweden 
Equipments Glass dish, shaker 
Procedures 
Preparation 
of the Gel for 
Transfer 
 
1. Partially hydrolyze the RNA sample, by soaking the gel in soaking solution 
0.01N NaOH/ 3M NaCl 10minx2 at room temperature. 
2. Move the gel containing fractionated RNA to a glass baking dish, use a sharp 
scalpel to trim away unused areas of the gel.  
3. Place a piece of thick blotting paper on a glass plate to form a support that is 
longer and wider than the trimmed gel.  
4. Fill the dish with transfer buffer until the level of liquid reaches almost to the 
top of the support. When the blotting paper is thoroughly wet, smooth out all 
air bubbles with a glass rod or pipette. 
Preparation 
of the 
membrane 
for transfer 
5. Use a fresh scalpel or a paper cutter to cut a piece of the appropriate nylon 
membrane~1mm larger than the gel in both dimensions.  
6. Float the nylon membrane on the surface of a dish of deionized H2O until it 
wets completely from beneath, and then immerse the membrane in 10xSSC 
for at least 5min.  
Assembling 
of the 
transfer 
system and 
transfer of 
RNA 
7. Carefully place the gel on the support in an inverted position. 
8. Surround, but do not cover, the gel with Saran Wrap. 
9. Wet the top of the gel with transfer buffer. Place wet nylon membrane on top 
of the gel so that the cut corner is aligned.  
10. Wet two pieces of thick blotting paper and place them on top of the wet nylon 
membrane. Smooth out any air bubbles with a glass rod. 
11. Cut a stack of paper towels (5~8cm high) just smaller than the blotting papers. 
Place the towels on the blotting papers. Put a glass plate on top of the stack 
and weigh it down with a 400g weight.  
12. Allow transfer of RNA for 3 hour in alkaline transfer buffer. 
Fix RNA on 
Membrane 
13. Dismantle the capillary transfer system. Transfer the membrane to a glass 
tray containing 50~300ml of 6xSSC at 23ºC to rehydrate the blot. Place the 
tray on a shaker and agitate the membrane very slowly for 5min. 
14. Remove the membrane from the 6xSSC and allow excess fluid to drain away. 
Put the membrane, RNA side upward, on a dry sheet of blotting paper for 2~4 
min. Fix the RNA to the membrane and proceed directly to prehybridization. 
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Table 19. Northern hybridization protocol 
Sheared DNA Sigma, St. Louis MO, USA 
Formamide Sigma, St. Louis MO, USA 
DENHARDT's solution Sigma, St. Louis MO, USA 
Reagents 
Stringent wash solution DAKO Cytomation, CA, USA 
Equipments Hybridize oven, shaker 
Procedures 
Pre-
hybridization 
1. Prewarm pre-hybridization solution in 68ºC water bath for 30min. 
2. Prehybridization-Incubate the membrane for 2 hours at 68ºC in 20ml of 
prehybridization buffer (0.2ml/cm2).  
3. Boil 200µg/ml of sheared salmon sperm DNA for 5min and chill on ice. 
Add formamide 5ml to the hybridization buffer.  
Hybridization 4. Add the denatured single-stranded probe 5µl (~100ng/ml) to 20ml 
fresh hybridization solution.  
5. Continue incubation for 12-16 hours at 45ºC.  
Stringent 
Washes 
6. Remove blots from hybridization solution and immerse in stringent 
wash solution TBST at 55ºC in a roller tube. 
7. Wash blots 10min while maintaining 55ºC for 3 times, using 1ml per 
cm2 of membrane for each wash. Gently shake the blot during the 
wash. 
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Table 20. Chromogenic development Protocol  
Reagents Chemiluminescent Detection 
system for Nuclei Acid Blotting 
DAKO Cytomation, CA, USA 
Method Alkaline phosphatase-conjugated anti-fluorescein antibody system 
Procedures  
Blocking 1. During the stringent wash step, prepare the blocking buffer at 
1:10 dilute with water in an incubation tray. 
2. Remove blots from the stringent wash and immerse in the diluted 
blocking solution at room temperature. 
Anti-FITC AP 
Conjugate 
Incubation 
3. Leave the blots in the tray, decant the blocking solution into a 
clean incubation tray. 
13. Add anti-FITC AP conjugate solution to the blocking solution to a 
final dilution of 1: 3200. Mix the solution in the tray, add the 
blocked blots. 
14. Incubate the blots in the conjugate solution for 30min at room 
temperature while gently shaking the tray. 
Washing 15. Decant the conjugate solution from the tray and rinse the blots 
twice using 25ml of TBST solution per blot for each time. 
16. Transfer the blots to a larger tray and wash an additional 3x 
10min at room temperature, using 2ml fresh TBST per cm2 of 
membrane for each wash. Gently shake during the washes. 
Chemilumine-
scent Substrate 
Incubation 
17. Transfer washed blots to a clean hybridization tube containing 
0.05ml of chemiluminescent substrate per cm2 of the membrane.  
18. Incubate for 5min at room temperature with gently shaking. 
Signal 
Development 
19. Drain the majority of the substrate from the blots by briefly 
holding blot up by a corner. Place the drained blots in individual 
plastic folders. 
20. Gently squeeze excess substrate and bubbles from the folder 
and seal the edges. The blots should still appear damp. 
21. Let the sealed blots incubate for 1hour at room temperature. 
Film Exposure 22. Place the sealed blots in a film exposure holder. 
23. Working in the dark, overlay the blot with X-ray film and close the 
holder. Expose 45min. Process the film. 
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Table 21. FISH Protocol 
Proteinase: 0.1% pepsin in 0.2N HCl DAKO,  Carpinteria, CA, USA 
DAPI II counterstain  VYSIS, DownerGrove, IL, USA 
NP-40 VYSIS, DownerGrove, IL, USA 
Dextran Sulfate Merck, Damstadt, Germany 
Reagents 
Formalmide Sigma, St. Louis MO, USA 
Equipment HYBrite 
Method Separate Denaturation Method 
Procedures 
Tissue 
preparation 
1. Cut tissue sections of 5um, place on Superfrost + slides and air dry 
at room temperature.  
2. Deparaffinize in xylenes three times for 5 minutes each. Hydrate 
sections gradually through graded alcohols: wash in 100% ethanol 
twice for 10 minutes each, then 95% ethanol twice for 10 minutes 
each. Wash in deionized H2O for 1 minute with stirring. Aspirate 
excess liquid from slides. 
3. Fix tissue sections in 4% paraformaldehyde in PBS (pH 9.5) for 
60min at room temperature. Wash twice with PBS for 3min each. 
4. Permeablize with 0.1% pepsin in HCl at 37ºC for 15min, wash with 
PBS 5 min.  
5. Soak sections with 50% formamide in 5x SSC. 
Denaturation 
and 
Hybridization 
6. Heat probe to 80ºC for 1min and iced, add to hybridization solution 
(50% formamide, 50% dextran sulfate), mix thoroughly. 
7. Apply probe mixture to slides. 
8. Place slides into a humifide chamber to hybridize at 55ºC over night. 
Post-hyb 
washing and 
chromogenic 
development 
9. Wash slides in 2xSSC, 50% formamide 15min at 55ºC to remove 
coverslip. 
10. Wash in 2xSSC, 50% formamide 30min at 55ºC. 
11. Wash in 0.2xSSC, 50% formamide 30min at 55ºC twice 
12. Equilibrate slides in 0.2xSSC 5min RT. 
13. Mount slides with DAPI. 
14. Coverslip and observe. 
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Table 22. Immunohistochemical Staining Protocol 
Anti-G-CSFR m-20 (sc-0694) 
Rabbit ABC staining system (sc-
2018) 
Santa Cruz Biochemicals, Santa cruz, 
CA 
Reagents 
Permount Shandon, UK 
Equipments Water bath 
Methods avidin-biotin horseradish based method (ABC)  
Slides 
preparation 
1. Cut 4-6 micron thick tissue sections.  
2. Deparaffinize in xylenes three times for 5 minutes each. Hydrate sections 
gradually through graded alcohols: wash in 100% ethanol twice for 10 
minutes each, then 95% ethanol twice for 10 minutes each. Wash in 
deionized H2O for 1 minute. Aspirate excess liquid from slides. 
3. Heat treatment: Place slides in a container and cover with 10 mM sodium 
citrate buffer, pH 6.0 Allow slides to cool in the buffer for approximately 20 
minutes. Wash in deionized H2O three times for 2 minutes each. Aspirate 
excess liquid from slides. 
4. Incubate for 5 minutes in 0.3% hydrogen peroxide in deionized H2O to 
quench endogenous peroxidase activity. Wash in PBS twice for 5 
minutes. 
5. Incubate specimens for 1 hour in 1.5% goat blocking serum in PBS.  
Antigen-
Antibody 
Reaction 
6. Incubate with 1/200 diluted primary antibody (1 µg/ml) for 30 minutes at 
room temperature or overnight at 4° C.  
7. Incubate for 30 minutes with biotin-conjugated secondary antibody (1 
µg/ml). 
8. Incubate for 30 minutes with avidin biotin enzyme reagent.  Wash 
sections in PBS for 5 minutes three time in between. 
Colorimetric 
staining and 
counterstain 
9. Incubate in peroxidase substrate as provided for 2-5 minutes, wash 
sections 5 minutes. 
10. Counter-stain in hematoxylin for 10 seconds. Immediately wash with 
several changes of deionized H2O. 
11. Dehydrate through alcohols and xylenes. Wipe off excess xylene.  
12.  Immediately add 1-2 drops of permanent mounting medium, cover with a 
glass coverslip and observe by light microscopy. 
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Table 23. Group distribution of tested animals 
Observation 
time 
Untreated Animal G-CSF 
treated 
Animal 
No operation N=5 REG 138~142 N=5 G-CSF 134~138 
90% PH  S 6h  N=5 REG-102~106 N=5 G-CSF 60~64 
90% PH  S 24h  N=5 REG-158~162 N=6 G-CSF 116~121 
90% PH  S 7d N=5 REG-170, 181,182, 
184,185 
N=5 G-CSF 84, 87, 89, 
90, 98 
Total N=20  N=21  
 
 
 
 
Table 24 Comparison of RT-PCR and PCR product 
Primer Len
-gth 
(nt)  
GC
% 
Tm 
(ºC) 
Pred-
icted 
length  
RT-
PCR 
result 
PCR 
result 
1F 5’- TCT GCC AGT GGG AGC CAG  
3R 3’-GGA GCC CGC AGA GCT CA 
18 
17 
66% 
58% 
60ºC 
58ºC 
480bp 500bp 500bp 
3F 5’- TGA GCT CCC ACT GGC AGA 
4R 3’- GGC TTC CAG AAC AGC TGC AC 
18 
20 
71% 
60% 
58ºC 
64ºC 
200bp 700 bp 200bp, 
700 bp 
4F 5’- GTG CAG CTG TTC TGG AAG CC 
5R 3’- GGG CCA TGG CAT GGA GTC 
20 
18 
60% 
67% 
64ºC 
60ºC 
270bp / / 
5F 5’- GAC TCC ATG CCA TGG CCC 
7R 3’- CAC TCC AGC TGT GCC CAG G 
18 
19 
67% 
68% 
60ºC 
64ºC 
350bp 500bp 800bp 
7F 5’- CCT GGG CAC AGC TGG AGT G 
9R 3’- ACT GGC GGG CTC CAG G 
19 
16 
68% 
75% 
64ºC 
56ºC 
150bp 600bp 600bp, 
800bp 
9F 5’- CCT GGA GCC CGC CAG T 
10R 3’- CAA GAG GGG CTG AGT GGA GTC 
16 
21 
75% 
62% 
56ºC 
68ºC 
650bp 800bp 700bp 
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Table 25. G-CSFR expression in normal rat tissues 
Organs Tissues Cell components 
Submucosa Endothelial cells Smooth muscles Fibroblast 
FISH + + + 
Mesenchy- 
mal cells 
IHC + + + 
Parenchyma Hepatocyte Bile duct cells Kupffer cells 
FISH Zone 2,3 + -- -- 
Liver  
IHC Zone 2,3 + extremely rare Trace level 
Cardio  Myocytes   
FISH +   
Heart 
IHC +   
Parenchyma Respiratory tract cells Type I pneumocyte Type II pneumocyte 
FISH -- -- + 
Lung  
IHC + -- + 
Parenchyma Proximal Tubular Outer medullary Inner medullary 
FISH + + +/- 
Kidney 
IHC + + -- 
Mucous Crypt Villi  
FISH Single cell + -  
Intestine 
IHC + +  
Parenchyma Acinar Islet Duct 
FISH Consistently + -- -- 
Pancreas 
IHC + + + 
 Lymphocyte FDC  
FISH - +  
Lymph 
node 
IHC - +/-  
 Lymphocyte IDC DRC 
FISH - - + 
Spleen 
IHC - +/- + 
 myeloid precursor cells granulocytes  and 
monocytes 
erythroid cells and 
megekaryocytes -- 
FISH moderate density + -- 
Bone 
marrow 
IHC + + -- 
FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; IDC, interdigitating cell; DRC, 
dendritic reticulum cell 
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Table 26 Comparison of G-CSFR protein expressions in different conditions. 
Organs Tissue/
Cell 
type 
Normal  90%PH 
S 6h 
90%PH 
S 24h 
90%PH 
S 7d 
G-CSF 
treated 
G-CSF 
90%PH 
S 6h 
G-CSF 
90%PH 
S 24h 
G-CSF  
90%PH 
S 7d 
Blood 
Vessels 
Endoth
elium 
+ +~++ +~++ +~++ +~++ +~++ +~++ +~++ 
Hepato
cyte 
+ + ++ + +~++ ++ +~++ + Liver 
Biliary 
cell 
- +/- +/- +/- + + + + 
Heart Myocyt
e 
+/- ++ + +/- + ++ + + 
Airways - +/- +/- + + ++ +~++ + Lung 
Pneum
ocyte 
- + + + + ++ +~++ + 
Cortex + +~++ +~++ ++ +~++ ++~+++ ++~+++ + 
Outer 
Medu 
- ++~+++ +~++ +~++ + ++ ++ + 
Kidney 
Inner 
Medu 
- ++ + + + +~++ ++ - 
Mucosa
-Villi 
+/- +~++ + + + +~++ +~++ +/- Small 
Bowel 
Crypt +/- +~++ + + + +~++ +~++ + 
Acinar + ++ ++ ++ ++ +++ ++ ++ 
Islet - +/- + + + + + 
Pancre
as 
Ducts + ++ ++ + + ++ ++ + 
+/- 
S, sacrifice; d, day; h, hour; Medu, medullary 
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Table 27. Cell Types Expressing G-CSFR in vitro or in vivo. 
 Cell type Species Reference  
Squamous carcinoma Human  (Noda et al., 1999) 
Colon adenocarcinoma  Human (Berdel et al., 1989) 
Glioma Human  (Mueller et al., 1999) 
Lung adenocarcinoma Human (Pei et al., 1998) 
Ovary carcinoma Human  (Brandstetter et al., 1998) 
Oral carcinoma Human (Tsuzuki et al., 1998) 
Small cell carcinoma of lung Human  (Tweardy et al., 1992) 
Tumorigenic 
cell lines 
Bladder transitional cell carcinoma Human  (Tachibana et al., 1995) 
Hematopoietic progenitor cells Human (Shimoda et al., 1992) 
Neutrophils Human  (Fukunaga et al., 1990a) 
Monocytes Human (Boneberg et al., 2000) 
Macrophages Human (Kuwaki et al., 1990) 
Megakaryocytes  
and platelet 
Human 
Mouse  
(Shimoda et al., 1993)  
(Saito et al., 1996) 
B-lymphocytes Human  (Morikawa et al., 2002) 
Immune 
cells 
T-lymphocytes Human (Matsushita and Arima, 
1998) 
Endothelium Human  (Bussolino et al., 1989) 
Fibroblast Human (Bussolino et al., 1989) 
Structural 
cells 
Neuron And glial cells  Rat  (Schabitz et al., 2003) 
Intestine  Human (Calhoun et al.  2000) 
Liver  Human (Calhoun et al.  2000) 
Kidney  Human (Calhoun et al.  2000) 
Eye  Human (Calhoun et al.  2000) 
Fetus 
Molar  Rat  (Otsuji et al., 1999) 
Others Placenta  Human  (Larsen et al., 1990)  
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 Figure 1A. Schematic diagram of human G-CSFR gene structure and 
primers designed for the rat gene. Six pairs of primers were designed 
based on the 10 conserved regions, named GR. Another pair of primer 
was designed for the G-CSFR probe, named PR.              
E exon; F forward primer; R reverse primer
 
 
 
 
 
 
a b
5’ 
ANGTATCGACTCACCTATAGGGCGAATTGAATTCCNCTTGGCCG
CGGAANTCGCCGCTTTGAGCTCTGCGGAGCTCCATCCAGTCTTC
TCCAAAGGGAAGACTCTTGTGGAGCCCATGGAGCTATACATCCC
AGCGGGTCTTAGGGATCAGGGCTCGGCTGCGACGTTCTGGAGA
TGGCATGGGCTGCAAAGGCCTCAGGTCTGCCTGCTGCTAGCTTG
CCTCACCCTCTGCCTCTCCATCCACACCCTAGATTAAGGAGATTG
TAGTGACTCTCAGATGTCCCTAAACGGGATCCGTGAGACGCGCT
GAACTCCTCTGCCTCTCTGGATTCTGCCTGTTGTTGCCCACAGGC
TCTCTCTCTCCCTTAGGCTACGCTAGTGTGGTCTTGAGACTGAAC
TTTCTTATTGGTGACACATCTGCGTGGGAAGGATGAAGGGATGG
AGCTTAGAGTGGGTCAGTGCCCTGGAGGCCCAGGCCAGAGGGG
CATGCCCTTCCCTGTATGCTGGGACTTCTCAATTACCAGCGATG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GAGGCACCTACTGTGCCTGGGTTTTCCCATCTGTAGAGTGGACA
Figure 1B. Partial sequence of the rat G-CSFR gene. A 500 nt-length 
nucleotide was sequenced (a). Results were compared with the database 
EMBL/Genbank/DDJB and aligned with the cDNA sequence of human and 
mouse G-CSFR gene (b). In the nucleotide sequence (c) red color indicates 
the consensus “WSXWS” (Trp-Ser-any residue-Trp-Ser) motif, violet color 
indicates a stretch that is highly specific for the rat G-CSFR. The lined 
sequence indicates the primers used in the amplification of G-CSFR probe 
for FISH. 
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Fig 2B. Electrophoresis of total RNA extracted from rat liver (lane 1), 
heart (lane 2), lung (lane 3), kidney (lane 4), intestine (lane 5), pancreas 
(lane 6), lymph node (lane 7), spleen (lane 8), and bone marrow (lane 9). 
28s rRNA and 18s rRNA are indicated by arrows. No major degradation 
331bp 
242bp
Fig 2C.  Detection of G-CSFR mRNA by RT-PCR. Total RNA extracted 
from normal rat tissues of liver (lane 1), heart (lane 2),  lung (lane 3), 
kidney (lane 4), intestine (lane 5), pancreas (lane 6), lymph node (lane 7), 
spleen (lane 8), bone marrow (Lane 9) was  tested. Amplicons were 
analyzed on 2% agarose gel and visualized by ethidium bromide 
        1             2              3              4             5              6              7            
fluorescein M indicated the marker      1            2             3             4            5             6              7             8    
Fl i 12 dUTP      1           2           3            4            5           6            7            8             9   
of the RNA was detectedFigure 2A. The PCR reaction using Fluorescein-12-dUTP (F), aminoallyl-
dUTP (A), and unlabeled nucleotides (U). Hundred-fold higher efficiency 
using unlabeled nucleotides or aminoallyl-dUTP compared to Fig 2D. Northern blot analysis of G-CSFR mRNA. Rat total cellular RNAs 
electrophoresis on formaldehyde agarose gels, hybridized with G-CSFR 
probe. All lanes contained 10ug of total RNA from : liver (lane 1), heart 
(lane 2), lung (lane 3), kidney (lane 4), intestine (lane 5), pancreas (lane 
6) lymph node (lane 7) bone marrow (lane 8) spleen (lane 9)
FISH 
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Figure 3. FISH analysis for G-CSFR mRNA in a normal rat. The blue 
areas represent the DAPI-I staining in the nuclei, green color represents 
FITC and indicates G-CSFR positivity. G-CSFR mRNA was detected in 
liver (A); heart (B);  lung (C); kidney (D); intestine (E); pancreas (F); 
spleen (G); and bone marrow (H).                                        
Original magnification: A H 600x; insert haematoxylin eosin 100x
 
 
 
 Liver  
 
 
 
No 
 
 
\ 
 
90%P
H  
S
 
 
 
 
90%P
H  
S
 
 
 
 
90%P
H  
S
 
 
 
  
Untreat G-CSF 
REG-140 G-CSF-135A E
REG-103 FG-CSF-064B
G-CSF-116REG-159 C G
G-CSF-084 HD
Figure 4. Immunohistochemical analysis of the G-CSF receptor in 
the rat livers. Immunoperoxidase stain, haematoxylin counterstain. 
Original magnifications: 100x (A);  200x (C, D, G); 400x ( B, E, F, 
G i t H)
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Figure 5. Immunohistochemical analysis of the G-CSF receptor in the 
rat hearts. Immunoperoxidase stain, haematoxylin counterstain.  
Original magnifications: 200x (A, C, D, E, F,H); 400x (B, G, H-insert). 
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Figure 6. Immunohistochemical analysis of the G-CSF receptor in 
the rat lungs. Immunoperoxidase stain, haematoxylin counterstain. 
Original magnifications:  200x (C, E, F, G, H); 400x (A, B, D).  
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Figure 7. Immunohistochemical analysis of the G-CSF receptor in 
the rat kidneys. Immunoperoxidase stain, haematoxylin counterstain. 
Original magnifications:  100x (B, C, D); 200x (G, H); 400x (A, D-
insert E F G insert H insert)
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Figure 8. Immunohistochemical analysis of the G-CSF receptor in the 
rat intestines. Immunoperoxidase stain, haematoxylin counterstain.  
Original magnifications: 200x (B, C, D, E, F, G, H); 400x (A, D-insert, 
H-insert).  
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 Figure 9. Immunohistochemical analysis of the G-CSF receptor in the 
rat pancreas. Immunoperoxidase stain, haematoxylin counterstain.  
Original magnifications: 200x (A, B, C, D, E, F, G); 400x (H).  
 
Abbreviations 
aa-dUTP 5-(3-Aminoallyl)-2’deoxyuridine 5’-triphosphate  
ABC avidin-biotin complex method 
ALL acute lymphocytic leukaemia  
ATL adult T-cell leukaemia  
BM bone marrow 
BMSCs bone marrow stem cells  
CD collecting duct  
CCD  Couple charged decive 
cDNA Complementary DNA 
CCEBP CCAAT/enhancer-binding protein  
CFU-Meg colony-forming units of megakaryocyte  
CRH cytokine receptor homologous  
DAPI 
4,6 diamidino-2-phenylindole in phenylenediamine 
dihydrochloride 
DEPC diethylprocarbonate  
DNA Deoxyribonucleic acid 
dNTP    deoxy-N-triphosphate 
DRCs Dendritic reticulum cells  
dTTP 2’deoxyuridine 5’-triphosphate 
E. coli Escherichia coli 
EB ethidium bromide 
EDTA    ethylene diamine tetraacetic acid 
FDC follicle dendritic cells  
FISH Fluorescence in situ hybridization  
FITC Fluorescein isothiocyanate  
fMLP f-met-leu-phe   
G-CSF                     Granulocyte colony-stimulating factor      
G-CSFR                  Granulocyte colony stimulating factor receptor                                                                                       
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GFs growth factors   
GM-CSF Granulocyte macrophage colony-stimulating factor  
H&E Hematoxylin-Eosin  
HPF high power field 
HSC hematopoietic stem cell  
I/RI ischemia/reperfusion injury  
IDCs Interdigitating cells  
IFN- γ interferon gamma 
IHC immunohistochemistry  
IL-1 β interleukin-1 beta 
IL-12 interleukin-12 
IL-6 interleukin-6 
IL-6R Interleukin-6 receptor 
IMCD inner medulla collecting duct  
JTK-1 Janus tyrosine kinase-1   
JTK-2 Janus tyrosine kinase-2  
KAc potassium acetate  
LN lymph node  
LPS lipopolyssacharide- 
MAPK mitogen-activated protein kinase   
MF   mitotic figures 
MNC mononucleocyte 
mRNA message  
MZ marginal zone  
NaCl sodium chloride 
NaOH sodium hydroxide  
NF-kB nuclear factor kB  
nt nucleotide 
OMCD outer medulla collecting duct   
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PCR polymerase cycle reaction  
PH partial hepatectomy  
PMN polymorphonucleocyte 
rhG-CSF recombinant human-G-CSF 
RNA Ribonucleic acid 
rRNA  ribosome 
RT-PCR Reverse transcript-PCR  
SDS     sodium dodecyl sulfate 
ssDNA single stranded DNA  
ssDNA single strand DNA  
STAT 3 signal transduction and activators of transcription 3  
TCR T-cell receptor  
TGFb-1 tissue growth factor beta-1 
Th T-helper/inducer lymphocytes 
Th2 T-cell helper 2 type 
TK-2 tyrosine kinase-2  
TNF-α tumor necrosis factor-alpha 
TPA phorbol ester  
uPA urokinase-type plasminogen activator  
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Summary 
Background: Binding of the ligand, Granulocyte colony-stimulating factor (G-CSF) to 
its receptor, the G-CSF receptor (G-CSFR), is instrumental for the action of G-CSF in 
the different issues.  
Aim: This study was designed to demonstrate the cellular distribution of G-CSFR in 
nonhematopoietic tissues of adult rats and the regulation of G-CSFR expression by 
administration of G-CSF and 90% partial hepatectomy (PH). 
Methods: Part of the extracellular domain of G-CSFR was sequenced. A G-CSFR 
specific ssDNA probe was designed. Asymmetric PCR using amino-allyl dUTP and 
secondary labeling with FITC was established. G-CSFR mRNA expression in bone 
marrow and nonhematopoietic organs (liver, heart, lung, kidney, intestine, lymph 
node, spleen and bone marrow) of normal rats was assessed by RT-PCR and 
Northern hybridization. The cellular distribution of G-CSFR mRNA was detected by 
fluorescent in situ hybridization (FISH). The G-CSFR protein expression was 
visualized using immunohistochemistry (IHC). Regulation of the receptor expression 
subsequent to 90% liver resection (6h, 24h, 7d) with and without G-CSF-treatment 
were investigated by IHC.  
Results: G-CSFR mRNA was found in all tested organs of normal rats by RT-PCR, 
and by Northern blot analysis. FISH and IHC on nonhemaopoietic tissue revealed G-
CSFR receptor expression in the cytoplasma of hepatocytes, cardiomyocytes, type II 
pneumocytes, proximal convoluted tubular cells, single enterocytes in the intestine, 
acinar cells of the pancreas. G-CSFR expression was induced by G-CSF 
administration. Upregulation of G-CSFR expression was prominent 6 hours after 
90%PH and an additive effect of G-CSF administration and 90%PH could be 
demonstrated. 
Conclusions: G-CSFR is expressed in parenchymal cells in adult rats. G-CSFR 
expression can be upregulated by the administration of G-CSF and by a major 
surgical trauma as shown in the model of 90% liver resection. G-CSFR expression 
was most prominent 6 hours after PH and an additive effect of combined G-CSF 
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treatment was revealed. This could indicate a possible biologic significance of G-
CSFR in the early phase of repair and regeneration processes. 
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